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Preface 
 
It is my belief that a few words of introduction are necessary in order to better understand this 
project. This project was undertaken using two separate research teams. One team was 
concerned with pharmacological in vivo experiments, mainly using rats and guinea-pigs, 
whereas the other research team concentrated on the development of chick retinas and worked 
in vitro. 
 
Both teams, however, concentrated on the characteristics of acetylcholinesterase (AChE). In 
the case of the nigrostriatal system in the rat brain (when taken in conjunction with a neuron-
degenerative central nervous system (CNS) disease), Parkinson’s disease causes a great 
reduction in the neuron transmitter dopamine (DA) in a specific part of the brain - namely the 
substantia nigra (SN). 
 
The first part of this study was conducted at the Department of Pharmacology in Oxford, 
England, while the second part was undertaken at the Institute for Zoology, Darmstadt, 
Germany. I proceeded as follows: First of all, I was interested in the behavioural effects of 
administering amphetamine to healthy animals and its effect upon the AChE in the SN. With 
the knowledge gained from those experiments, I wanted to examine the effect that an 
introduction of amphetamine would have upon sick animals (6-OHDA is a neurotoxin). The 
6-OHDA in damaged animals is comparable to Parkinson’s disease in humans. This 
experimental model was developed as it is not ethically permissible to conduct this type of 
research on humans. 
 
Amphetamine was administered to substantially increase the concentration of DA at the 
synapses. To our advantage, we understand that in most cases of Parkinson’s, the SN has been 
damaged consequently less DA will reach the basal ganglia. Using this method we are able to 
recognise the signs and symptoms of this disease. Present day treatment of Parkinson’s is 
based on this theory, particularly the introduction of L-Dopa (an essential building block for 
DA, since DA cannot pass through the blood brain barrier) in order to replenish basal ganglia 
with a DA deficiency. 
 
Amphetamine, however, is not the only drug to have an effect upon the DA system, thus my 
desire to test other pharmaceuticals. Apomorphine, a mixture of D1/D2 agonist, is a substance 
which binds and stimulates D1 and D2 receptors and thereby strengthens natural processes. 
Another substance was quinpirole, a selective D2 agonist. Glutamate receptors are found on 
dopaminergic neurons of the SN pars compacta. Glutamate is an important neuron transmitter 
stimulant and its agonist NMDA could facilitate the release of DA to the SN. The knowledge 
gained made me want to learn more about the effects of NMDA. 
 
With the results of my experiments and the acquired knowledge, I returned to Germany where 
I pursued my interest in the basal ganglia and tried, with success, to cultivate the homologous 
structures of the SN and their DAergic neurons in baby chicks. 
 
 
Kronberg/Schönberg      Bettina Heiland 
Winter 2001/02 
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ABSTRACT 
 
The exact role and function of the CNS is extremely complex and, despite decades of 
research, still not clearly understood. Malfunction of the basal ganglia has been implicated in 
several diverse neurological disorders such as Alzheimer’s disease, hemiballism and of most 
interest to this study, Parkinson’s disease. The main topic of this thesis is the substantia nigra 
and, in particular, the apparent relationship between dopamine and acetylcholinesterase in this 
region. An understanding of the mechanisms that influence the development and regeneration 
of the dopaminergic neurons of the nigro-striatal pathway is of particular importance since it 
is the death of these neurons that causes Parkinson’s disease. Numerous neurotransmitter or 
neuromodulator substances are found in the CNS, the distribution, fibre connections and 
ultrastructure of the peptidergic system have been explored, though little is known about their 
function. Colocalisation of classical neurotransmitters and neuropeptides is a widely accepted 
feature of neurons in many parts of the CNS. 
The materials and methods chapter provides a detailed account of the experimental procedures 
used in this thesis. Particular reference is made to the on-line chemiluminescent system, as 
this procedure is not used outside Prof. Dr. S.A. Greenfield’s laboratory. 
The experimental chapters presented in this thesis fall into three main sections. The first set of 
experiments determine whether a relationship exists between dopamine, the regulation of 
AChE- release in the substantia nigra of the rat and concomitant behaviour following different 
drug stimulations in naive and 6-OHDA lesioned rats. The experiments indicated that 
different drug stimulations in naive animals and in 6-OHDA animals have an influential effect 
on the release of AChE and behaviour. In addition, the local or systemic application of 
amphetamine significantly increased the spontaneous release of AChE in the substantia nigra 
and concomitant behaviour in naive animals. Apomorphine, quinpirole and NMDA showed a 
lesser effect. Neurotoxin pre-treatment significantly reduced AChE-release in the substantia 
nigra and dopamine content of the ipslateral striatum. Amphetamine applied locally to 
lesioned animals showed no significant increase in the release of AchE, but did produce a 
significant return from robust basal circling to normal behaviour. In contrast to this, the 
systemic application of amphetamine increased the release of AChE and the level of both 
contraversive and ipsiversive circling behaviour. Sham-operated animals showed results 
similar to those achieved with the naive animals.  
In the second study, a new animal model was established using (E18) embryonic chicks 
(Gallus gallus domesticus), the aim of which was to determine the development of mid-brain 
dopaminergic neurons in organotypic slice culture and the development and regeneration of 
chick dopaminergic neurons of the ventral mesencephalon. It was possible to culture single 
ventral mesencephalon slices of the chick. Cultures were stained for tyrosine hydroxylase. 
When the culture medium was supplemented with AChE, the level of growth in tyrosine 
hydroxylase-immunoreactive neurites was not changed. Addition of a specific inhibitor of 
AChE, BW284c51, caused cell death. 
In the discussion chapter, the general findings and conclusions of this thesis are discussed in 
the light of previously published work. Furthermore, the possible role and function of the 
relationship between the dopaminergic and cholinergic systems are suggested, and future 
proposals are made regarding continued research which would both extend and clarify further 
the findings of this thesis. 
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CHAPTER 1 
 
 
1 INTRODUCTION AND AIM OF THIS WORK 
 
 
Introduction 2
1 Introduction 
 
 
In 1817, James Parkinson gave the first account of a disease which he described as `shaking 
palsy´ which is more commonly known today as Parkinson’s disease (Parkinson, 1817). The 
disease is characterised by three major symptoms: a trembling of the limbs coupled with 
inferior movements and rigidity. These symptoms can also be accompanied by a stooped, 
shuffling walk and an inability to maintain an upright stature. The exact cause of the disease is 
unknown. However, various factors may be involved in the aetiology of the disease, including 
the environment, genetics, toxins, post-viral damage and free-radical formation. Moreover, a 
loss of dopaminergic neurones in the pars compacta region of the substantia nigra is present in 
all cases. This loss of neurones, particularly in the nigrostriatal pathway, leads to a lower 
release of dopamine in this projection and a reduction in the interaction of two major parts of 
the basal ganglia: the striatum and the substantia nigra. Despite extensive research in the field, 
the questions as to why the nigrostriatal pathway degenerates and why the nigral dopaminergic 
population of neurons is so vulnerable remain unanswered. 
 
1.1 The basal ganglia 
The role and function of the basal ganglia, which consists of the globus pallidus, the striatum, 
the subthalamic nucleus and the substantia nigra, is very complex. The exact role and function 
of this area is complicated and still not clearly understood. Malfunction of the basal ganglia 
has been implicated in several diverse neurological disorders such as Alzheimer’s disease, 
hemiballism, and, of most significance to this study, Parkinson’s disease. The basal ganglia is 
thought to be involved in the control of movements. However, there are no direct connections 
between any of its regions and the spinal cord, and, as a result, no direct control of muscle 
contraction. The basal ganglia contains multiple internal pathways involving a multitude of 
neurotransmitters (Trepel, 1999). The main reason for such extensive interest in the structure 
of these areas is the loss of function they experience when affected by several widespread, 
and, as yet incurable, neurological diseases. The main regions of the basal ganglia that are 
studied in this thesis are the striatum, substantia nigra and the nigrostriatal pathway. The 
striatum, which comprises the caudate nucleus and putamen, is the largest cell mass in the 
basal ganglia. This region receives projections from the cerebral cortex, the central median 
nucleus of the thalamus and from the substantia nigra (nigrostriatal pathway). Within the 
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striatum there are various levels of compartmental organisations, including a mosaic 
organisation of neurochemical systems related to neuroanatomical connections. Thus, the 
mosaic organisation into `patchwork´ and histologically-distinct `matrix´ compartments 
reflects the heterogeneous distribution of neuroanatomical markers. The striatum contains 
densely-packed neurons and, for this reason, the first level of compartmental organisation is 
divided into separate populations of neurones. A primate’s substantia nigra, which literally 
means black substance, is characteristically black in colour because of the presence of a high 
concentration of neuromelanin pigment in the pars compacta region. The substantia nigra can 
be divided into three regions, pars lateralis, pars compacta (from where cells innervate the 
striatum) and pars reticulata (from which cells innervate the thalamus, superior colliculus and 
pedunculopontine nucleus). The pars compacta, the dorsal layer of the substantia nigra, 
contains neurones with no collaterals which project into the striatum. The vast majority of 
neurones are dopaminergic in nature. These dopaminergic neurones are densely-packed A9 
neurones. In the ventral segment, dopaminergic dendrites exist which extend into the pars 
reticulata region. In the dorsal segment, dendrites of dopaminergic neurones extend to the 
mediolateral pars compacta. The dopaminergic neurones of the pars compacta continue into 
the striatum, on medium spiny output neurones which then project back to the substantia 
nigra. The pars reticulata, the ventral layer of the substantia nigra, is composed of efferent 
neuronal populations mixed with interneurones. In this region, the neurones are surrounded by 
more glial cells than those in the compacta region and the neurones are also less densely 
packed. The majority of the neurons project to structures outside of the substantia nigra, such 
as the superior colliculus, the thalamus and pedunculopontine nucleus. The majority of 
neurons in the pars reticulata are GABAergic. One of the connection pathways between 
substantia nigra and striatum is the nigrostriatal pathway. The nigrostriatal pathway 
transports neurochemicals from the substantia nigra to the striatum. The majority of 
dopaminergic neurones which form this pathway originate from the A9 cell group of pars 
compacta neurones, and, in most cases, synapse on dendrites of striatal output neurones. A 
selective loss or deficit in the substantia nigra pars compacta neurones produces clear deficit 
in locomotor activity, e.g. in Parkinson’s disease and its equivalent animal models. 
 
1.2 Dopamine in the nigrostriatal pathway 
It has been known for more than 20 years that dopamine is spontaneously released from 
dendrites of dopaminergic nigrostriatal neurones. It was shown, in vitro, that the application of 
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depolarising concentrations of potassium caused a dendritic release of dopamine in a calcium-
dependent manner (Geffen et al., 1976). In addition, in vivo studies showed that both 
amphetamine and depolarising concentrations of potassium could evoke a dendritic release of 
dopamine (Nieoullon et al., 1977). It has been suggested that dopamine is stored in the smooth 
endoplasmic reticulum (SER) (Henderson and Greenfield, 1984). Within the substantia nigra 
and the nigrostriatal pathway there are three types of dopaminergic receptors: D1 (pars 
reticulata), D2 and D3. Once released from within the substantia nigra, dopamine diffuses 
through the extra-cellular space and can act on these receptors on nigrostriatal neurones, 
whereby it is most potent on D3 receptors. 
 
1.3 Acetylcholinesterase in the central nervous system 
There are two different enzymes present in vertebrates that can hydrolyse acetylcholine; 
acetylcholinesterase (AChE, EC 3.1.1.7) is acknowledged as the enzyme that rapidly 
hydrolyses the neurotransmitter acetylcholine to acetate and choline. For this reason, it is 
absolutely necessary in order to maintain continuous synaptic transmission. The hydrolysis of 
acetylcholine by AChE takes place very quickly and is almost as fast as the maximal 
theoretical limit set by molecular diffusion of the substrate (Rosenberry, 1975). The existence 
of AChE was postulated by Dale in 1914 and demonstrated by Loewi and Navratil in 1926. In 
1937, Marnay and Nachmansohn observed high concentrations of AChE at neuromuscular 
junctions and in the electric organs of Torpedo and Electrophorus (see Massoulié, 1993). The 
other form of cholinesterase is butyrylcholinesterase (BChE, EC 3.1.1.8), also called non-
specific cholinesterase or pseudocholinesterase. It is present in serum and has no known 
physiological function. Although BChE can hydrolyse acetylcholine, (albeit three times less 
effective than AchE), it can also hydrolyse many other esters. AChE is predominant in 
muscles, in red blood cells, in the brain and in the peripheral nervous system, while BChE is 
mainly synthesised in the liver and secreted into the plasma, as well as being present in the 
brain. There is an additional variation between these two enzymes in that BChE exhibits 
maximum activity of acetylcholine hydrolysis in high concentrations of the transmitter 
acetylcholine; with these levels of acetlylcholine, AChE is inhibited by excess substrate 
(Massoulié and Bon, 1982). Evidence to date indicates that there is no correlation between the 
distribution of the two enzymes in various tissues; however, a lack of AChE is fatal. In 
contrast, certain human individuals can be deficient in BChE or even lack it, without any 
physiological consequences. 
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For many years, it was acknowledged that the sole function of the only form of AChE known 
at that time (the membrane-bound form) was the termination of cholinergic neurotransmission. 
Over the last forty years, these views have changed considerably, particularly with the 
detection of multiple forms of AChE and also with the discovery of soluble forms of AChE on 
the periphery and in the central nervous system. 
 
AChE displays a very rich molecular polymorphism, for they exist as membrane-bound, basal 
lamina-anchored or soluble forms. They can exist as monomers or oligomers consisting of 
glycoproteic catalytic sub-units. Furthermore they can be distinguished on the basis of their 
quarternary structure; for example globular (G), containing one, two or four subunits (G1, G2 
and G4 respectively), and asymmetric (A) forms, consisting of one to three globular tetramers 
(A4, A8 and A12) (Massoulié and Bon, 1982). 
In the mammalian CNS, the predominant form of AChE is the G4 form. This can be further 
subdivided into the hydrophilic/soluble G4 (20% of total G4) and the membrane-bound G4 
form (approximately 80% of total G4). Chubb and Smith (1975a) were the first to show 
secretion of the soluble G4 form of AChE in bovine adrenal medulla. In the CNS, AChE has 
been located within the cell body, dendrites (Henderson and Greenfield, 1984), axons of 
dopaminergic neurones in the substantia nigra, and within noradrenergic neurones in the locus 
corruleus. It was not until 1979 that AChE-release in the substantia nigra was first 
demonstrated (Greenfield and Smith, 1979). Further examination of this phenomenon revealed 
that the protein appears to be released from the dendrites of pars compacta dopaminergic 
neurones in this region (Greenfield et al., 1983b) in a similar way to dopamine (Greenfield, 
1991) and the dendritic release of AChE has been shown to be evoked by a dendritic calcium 
conductance (Greenfield, 1985; Linás et al., 1984; Linás and Greenfield, 1987). Perhaps one of 
the greatest advances in the understanding of the relevance of dentritic release of AChE in the 
substantia nigra has come with the development of an `on-line´ chemiluminescent system 
which permits the continuous release of AChE in the region being monitored (Taylor et al., 
1989). Recent studies using this system have indicated that the release of AChE can be 
correlated with motor activity and sensory stimulation (Jones et al., 1991, 1994). 
 
In a similar fashion to other glycosylated membrane and secreted proteins, cholinesterases, in 
particular AChE, are synthesised in the rough endoplasmic reticulum and translocated to the 
lumen where signal peptides are cleaved. Histochemical studies carried out by Henderson and 
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Greenfield (1984) showed that AChE is in the SER and the Golgi apparatus of the dendrites in 
the substantia nigra. In addition, it was also reported that AChE was present in the extra-
cellular space surrounding these pars compacta neurons. 
In the early 1980s, it was observed that in vivo AChE release could be evoked in the substantia 
nigra and that this release was calcium-dependent (Greenfield et al., 1980; Greenfield et al., 
1983a). 
 
Over 20 years ago, a highly controversial theory proposed that cholinesterases may have non-
classical functions (Silver, 1974). In the last two decades, this theory has slowly gained 
widespread acceptance. The key observation that led to the hypothesis of non-classical 
functions for AChE was that AChE may be present in areas unrelated to cholinergic 
transmission. Cholinesterases are widely distributed both in the central and peripheral nervous 
systems as well as in serum and other non-neuronal tissues. Such `non-cholinergic´ 
cholinesterases have been observed in non-neuronal structures (e.g. plasma, erythrocytes, 
lymphocytes, thymocytes, megakaryocytes), as well as neurons from various regions (e.g. 
cerebellum, locus coeruleus, dorsal raphé nucleus). Henderson and Greenfield (1987) showed 
that the substantia nigra is a brain region that contains disproportionately high amounts of 
AChE. Moreover, AChE within the substantia nigra is associated with the dopaminergic 
neurons of the pars compacta region (Henderson and Greenfield, 1984). Using electron 
microscopy, it was demonstrated that nigral AChE is localised within the Golgi apparatus, the 
smooth endoplasmic reticulum of dopaminergic pars compacta neurons and their dendrites, and 
to the surface and surrounding extra-cellular space of these cells (Henderson and Greenfield, 
1984).  
As soluble AChE is present in cerebrospinal fluid (CSF), Greenfield and Smith (1979) 
investigated release of AChE during stimulation of specific brain regions. Electrical stimula-
tion of the caudate nucleus, substantia nigra or hypothalamus led to an increase in the detectab-
le activity of AChE in CSF sampled from the cisterna magna of rabbits. Since this initial study, 
much data has been accumulated on the release of AChE from the substantia nigra. AChE 
release may be evoked by a depolarising concentration of potassium ions (Greenfield et al., 
1983) and is independent of cholinergic receptor stimulation (Weston and Greenfield, 1986). 
Furthermore, stimulation of both the dorsal raphé nucleus (Dickie and Greenfield, 1994; Dickie 
and Greenfield, 1995) and the subthalamic nucleus (Jones et al., 1994) evoke nigral release of 
AChE. More recently, a relationship between AChE release and the synthesis of dopamine has 
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also been demonstrated (Dally and Greenfield, 1994; D. Phil. thesis Dally, 1996). Greenfield 
(1991) proposed that AChE release may be mediated by a special calcium conduction seen in 
the dendrites of dopaminergic pars compacta neurons. Since the release of a soluble form of 
AChE is not required by the molecule to carry out its classical role, this release could be a 
feature of the molecule’s non-cholinergic functions in connection with dopaminergic nigral 
neurons. 
 
Many lines of evidence have supported the hypothesis first suggested by Drews (1975) which 
put forward that an alternative role for AChE could be related to neuronal development. During 
development, it has been demonstrated that a temporal shift in expression of AChE forms 
exists. The shift is from the monomeric (G1) and dimeric (G2) forms, which have a lower 
molecular weight, to the tetrameric form (G4), which has a higher molecular weight. This shift 
has been shown to occur in several species including the chick (Layer et al., 1987), quail 
(Anselmet et al., 1994), mouse (Inestrosa et al., 1994), and rat (Muller et al., 1985). 
 
The reasons for suggesting a morphogenic role for AChE have been based on the finding that 
expressions of AChE can change or disappear totally during the course of development. It has 
been proposed that this `embryonic´ AChE is non-cholinergic and does not change choline 
acetyltransferase levels, since choline acetyltransferase (the synthesising enzyme for 
acetylcholine) does not show similar transient expression patterns and lesions that inhibit 
AChE in projection fields (Robertson and Yu, 1993). Layer and colleagues found that the 
transient expression of AChE in the chick embryo corresponds to the period of increased 
differentiation and neurite extension. Interestingly, BChE expression precedes that of AChE 
and thus corresponds to periods of cellular proliferation (Layer, 1983; Layer and Sporns, 1987; 
Layer, 1991; Willbold and Layer, 1992). Since this group also found that BChE expression and 
AChE expression were mutually exclusive (Layer, 1983), they propose the following scheme: 
BChE has a role in the proliferation of cells but once levels of BChE start to drop i.e. at the end 
of the proliferative phase, levels of AChE rise. Thus, AChE could have a role in the control of 
neurite extension and synaptogenesis (Layer and Willbold, 1995). 
 
More direct evidence that AChE has a morphogenic function was provided by Gupta and 
Bigbee (1992) who showed that the level of AChE activity in cultured dorsal root  ganglion 
neurons varied according to the permissiveness of the substratum to neurite outgrowth. Layer 
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et al. (1993) also demonstrated that AChE is actively involved in neurite outgrowth since the 
extent and pattern of tectal and retinal neurites was altered by cholinesterase inhibitors 
(BW284c51 and the BChE inhibitors ethopropazine and bambuterol). Dupree and Bigbee 
(1994) found that treatment with a cholinesterase inhibitor (BW284c51) retarded neuritic 
outgrowth and neuronal migration of cultured basal root ganglion neurons. A stimulatory 
action of AChE has been further supported by recent studies. Small et al. (1996) showed that 
when dissociated chick brain or sympathetic neurons were grown on plates pre-coated with 
purified AChE and heparan sulfate proteoglycans, neurite outgrowth was strongly stimulated. 
Srivatsan and Peretz (1996) demonstrated that the stimulatory action of Apalysia hemolymph 
on cultured pedal dopaminergic neurons is mediated by AChE. 
 
1.4 Monitoring of in vivo AChE release using the `on-line´ chemiluminescent technique 
Neurochemical release can be measured by a wide variety of techniques, depending on the 
neurochemical under investigation and its location within the central nervous system. These 
techniques adopt one of two approaches, either measuring the release of the neurochemical into 
CSF (CSF sampling) or measurement of neuroactive substances released directly into the 
intercellular space (cortical cup method, microdialysis, in vivo voltammetry, push-pull 
technique). These techniques are very versatile and adaptable, but are all unsuitable for 
measuring and quantifying the in vivo release of AChE in the substantia nigra of freely moving 
animals. This problem has now been overcome with the development of the `on-line´ 
chemiluminescent technique (Taylor et al., 1989). The `on-line´ chemiluminescent system was 
the most fundamental procedure used in this thesis. This technique has been operational for 
less than ten years and is still classed as relatively new. This assay has been previously used 
solely to determine the activity of AChE released in the guinea-pig substantia nigra (Jones and 
Greenfield 1990, Jones et al. 1991, Jones et al. 1994, Dally and Greenfield 1994).  However, 
more recently this assay has been adapted for use with the rat (Dally et al. 1996). 
 
The `on-line´ chemiluminescent technique is actually a combination of two well established 
protocols, the push-pull perfusion method (first devised by Fox and Hilton, 1958) and the 
chemiluminescent assay developed by Israel and Lesbats (1981). In 1987, Linás and Greenfield 
carried out the first `on-line´ visualisation of dentritic release of AChE from mammalian 
substantia nigra neurones in vitro. In this system, the brain slice was placed in a bath so that it 
was immersed in a continuous flow of Ringer’s solution containing luminol, choline oxidase 
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and microperoxidase. The chemiluminescent reaction was initiated by the introduction of 
acetylcholine chloride to the system and the light emitted by the slice was detected using a 
`light cell´ connected to a photomultiplier tube. In order to quantify the signal, the output from 
the photomultiplier tube was amplified and displayed on a chart recorder. This system was 
ideal for measuring AChE release in vitro. To measure the release of AChE in living animals, 
Taylor et al. (1989) overcame some problems (i.e. the pH value was highly toxic for living 
animals, and the images of AChE-release in the substantia nigra could not be visualised 
because of the animal’s skull) by devising a technique whereby the activity of the AChE 
released inside the animal could be analysed continuously and ex situ. Taylor et al. (1989) 
combined the push-pull technique with the chemiluminescent reaction and incorporated both 
protocols into an assay system in which AChE activity in the push-pull cannula perfusate could 
be continuously monitored. In the last six years, the `on-line´ chemiluminescent system has 
been adapted further. It is now possible to monitor AChE release in freely-moving animals and 
compare the spontaneous and evoked release of AChE into the substantia nigra (Jones and 
Greenfield, 1991; Jones et al., 1994; Taylor et al., 1990) or the striatum (Dally D, Phil. thesis, 
1996) of moving animals. This technique also permits determination of the effect of drugs and 
toxins on the spontaneous release of AChE in these regions. Furthermore, it is possible to 
quantify any animal movement in parallel with AChE release in the substantia nigra. 
 
Following the perfusion of the substantia nigra with ACSF, the perfusate containing 
neurochemicals within it was pumped out of the substantia nigra through the cannula. The 
outflow of the cannula was then introduced to the flow of the reagents required for the assay. 
The first exogenous AChE diluted in ACSF was exposed to the flow of a solution containing 
acetylcholine and choline oxidase independently. The hydrolysis of the acetylcholine by AChE 
and the resultant oxidation of choline produced from this reaction by choline oxidase produces 
hydrogen peroxide. The passage of this mixture of solution through a cold incubator preserves 
the hydrogen peroxide prior to its introduction into the flow of solution containing luminol, 
horseradish peroxidase and microperoxidase in a `light-cell´ located in front of a 
photomultiplier tube. In the presence of hydrogen peroxide, luminol was oxidised and light 
produced. The output signal was then amplified and displayed on a chart recorder and 
oscilloscope. A residual light signal was obtained from the spontaneous hydrolysis of 
acetylcholine. The assay was able to measure the continuous release of AChE and is sensitive 
enough to detect AChE activity to a level as low as 0.01 mU. A five-second pulse of AChE 
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was detected (Jones D. Phil. thesis, 1992). This system was extensively used to carry out the 
research for this thesis. 
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1.5 The aim of this work 
 
Parkinson’s disease cannot be cured, but as is the case with so many other disorders of the 
nervous systems, it can be controlled by therapy. This gave me the incentive to delve deeper 
into this area. 
 
Parkinson’s disease is an ailment exclusive to humans. Ethics forbid the use of human 
subjects, so it was of critical importance to find a substitute creature in the phylum vertebrata 
which could be artificially infected with the illness. The rat is an example of such mammals. 
Furthermore, I was also looking for another object in the phylum vertebrata for the sake of 
comparison. The nearest in the class was aves, and a publication using this bird already 
existed which related to my work. Last but not least, being a member of Professor Layer’s 
working group gave me new possibilities to extend my studies further. 
 
As time goes by, substantial evidence is being accumulated to support the idea of a non-
cholinergic action of AChE. If AChE has a novel role in the substantia nigra, the question that 
has to be addressed is whether it involves any interaction with dopamine, the major 
transmitter in this system. 
 
The purpose of this thesis is to provide an understanding of the development of dopaminergic 
neurones using chick brain, and to examine the normal and pathological nigrostriatal pathway 
of the rat brain in connection with a noncholinergic function of AChE. 
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2 Materials and Methods 
 
 
2.1 Materials 
 
 
2.1.1 Reagents 
 
reagent source of supply 
(-)-quinpirole HCl RBI, USA 
2-methyl-3-(3,4-dihydroxy-phenyl)-L-alanine (DOPA) Sigma, Poole 
3,3’-diaminobenzidine (DAB) Sigma, Deisenhofen 
3,4-dihydroxyphenylacetic acid (DOPAC) Sigma, Poole 
5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB) Sigma, Poole 
6-hydroxydopamine (6-OHDA) Sigma, Poole 
95% O2/5% CO2 BOC, UK 
acetylcholine-chloride (ACh) Sigma, Poole 
acetylcholinesterase (AChE) Sigma, Poole 
acetylthiocholine iodide (ATC) Sigma, Deisenhofen/Poole 
alcohol BDA, Poole 
aluminia, for column chromatography Sigma, Poole 
ammonium nickel(II)sulfate hexahydrate Sigma, Deisenhofen 
amphetamine Chris Webb, Oxford 
apomorphine hydrochloride Sigma, Poole 
avidin-peroxidase Sigma-Aldrich Chemie, Germany 
boric acid (H3BO3) Sigma, Poole 
bovine serum albumine (BSA) Sigma, Deisenhofen 
calciumchloride (CaCl2) Sigma, Poole 
choline oxidase Sigma, Poole 
chromic potassium sulphate (CrK[SO4]2) Sigma, Deisenhofen 
cicken serum (CS) Gibco, Eggenstein 
citric acid (C6H8O7) Sigma, Poole 
cresyl violet acetate Sigma, Poole 
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cupric sulfate (CuO4S) Sigma, Deisenhofen/Poole 
cytosine-β-D-arabinofuranoside Sigma, Deisenhofen 
di-sodiumhydrogenorthophosphate (Na2HPO4) BDA, Poole 
dopamine (DA) Sigma, Poole 
DPX Sigma, Poole 
Dulbecco’s modificated eagle minimal medium (DMEM) Gibco, Eggenstein 
ethylenediaminetetra-acetic acid disodium salt (EDTA) Sigma, Poole 
F12 medium Gibco, Eggenstein 
fetal calf serum (FCS) Gibco, Eggenstein 
Folin & Ciocalteu’s phenol reagent BDH, Poole 
formaldehyde (solution 37%) Sigma, Deisenhofen 
gentamycin sulfate BioWHITTAKER, Maryland 
Geys balanced salt solution (GBSS) Sigma, Deisenhofen 
glutamine BioWHITTAKER, Maryland 
glutathione (GSH, C10H17N3O6S) Sigma, Poole 
halothane-M&B Rhône Mérieux, UK 
horseradish peroxidase (HRP) Sigma, Poole 
hydrogen peroxide, solution 35% (H2O2) Merck, Darmstadt 
Kaiser’s glycerinegelatine Merck, Darmstadt 
l-ascorbic acid, free acid Sigma, Poole 
luminol (C8H7N3O2) Sigma, Poole 
magnesiumchloride (MgCl2) Sigma, Poole 
maleic acid Sigma, Deisenhofen 
microperoxidase Sigma, Poole 
NMDA Dr. S. Cragg, Oxford 
P.E.P. powder Intervet Laboratories LTD 
penicilline/streptomycine BioWHITTAKER, Maryland 
perchloric acid (HClO4) Sigma, Poole 
plama chicken Sigma, Deisenhofen 
plasma, chicken Sigma-Aldrich Chemie, Germany 
potassium hexacyanoferrate Sigma, Poole 
potassiumchloride (KCl) BDA, Poole 
potassiumdihydrogenorthophosphate (KH2PO4) BDA, Poole 
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potassiumdihydrogenphosphate (KH2PO4) Sigma, Poole 
saccharose Merck, Darmstadt 
Sagatal (Pentobarbitone Sodium B.P.) Rhône Mérieux, UK 
simplex rapid: dental cement, dental acrylic Astenal Dental products 
sodium carbonate (Na2CO3) Sigma, Poole 
sodium chloride solution, 0.9%, sterile Sigma-Aldrich Co., UK 
sodium hydrogen carbonate (NaHCO3) Sigma, Poole 
sodium hydroxide (NaOH) Sigma, Poole 
sodium potassium tartrate (Rochelle salt) Sigma, Poole 
sodium tetraborate (BORAX) Sigma, Poole 
sodiumchloride (NaCl) BDA, Poole 
tetraisopropylpyrophosphoramide (iso-OMPA) Sigma, Deisenhofen 
thrombin Sigma, Deisenhofen 
thrombin, bovine Sigma-Aldrich Chemie, Germany 
Tissue Tek O.C.T. 
trishydroxymethylaminomethane (Tris) Sigma, Poole 
Triton X-100 Sigma, Deisenhofen 
Trizma BASE Sigma, Poole 
Trizma HCl Sigma, Poole 
uridine Sigma, Deisenhofen 
xylene Sigma, Poole 
 
 
2.1.2 Equipment 
 
equipment source of supply 
bench centrifuge 112 Sigma 
camera CCTV Hitachi 
centrifuge 3K10 Sigma 
chartrecorder TE 850 Tekman 
chromjet integrator SP 4400 Spectra Physics Analytical 
CO2-incubator B5060 Heraeus, Hanau 
CO2-Water-Jacketed incubator Nuaire, USA 
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column apex octadecyl 5mm reverse phase Jones Chromatography 
computer RM NIMBUS Research Machines Oxford 
cotton buds 
cryostat HM500OM Microm, Walldorf 
cryotome Leitz, Wetzlar 
current-to-voltage amplifier/converter purpose-built 
digital timer Smiths 
dissecting equipment neoLab 
drill Quayle Dental, Worthing 
drill-heads Kornet CARBIDE, Germany 
egg-incubator Jung 
electrochemical detector Waters 460 Millipore 
ento pins 38X40 mm Asta, Tipton 
FM/modulating/demodulating circuits purpose-built 
glass capillaries, borosilicate World Precision Instruments, USA 
gyratory shaker purpose built 
Hamilton syring 5.0µl Hamilton Co. Reno. Nevada 
hotplate B212 Bibby 
injector Rheodyne, California 
lamina flow hood BDK Luft-/Reinraumtechnik 
laminar air flow gelaire Gelman Instruments 
laser printer HL-8e Brother 
metal sheets for rat cages North Kent Plastic, Kent 
micolance 3 0.8X40 Becton Dickinson 
Micro Injection Unit model 5000 KOPF Tujunga, Ca. USA 
microscope Diaplan Leitz 
modified videogram purpose-built 
monitor Hitachi 
needle printer LQ-850 Epson 
oscilloscope DSO 420 Gould 
ph-meter 
photomultiplier housing, containing photomultipier tube purpose-built 
photomultiplier tube power supply unit purpose-built 
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pump LKB HPLC 2248 Pharmacia 
pumps minipuls 2 Gilson 
PVC Manifold tubing Altec, Alton 
razor blade tools Gem 
razor blades 
S/S Hypo needle tubing 
solenoid/relay controller purpose-built 
stereo tactic frame 
sterile filters (type AC) sartorius, Göttingen 
syring SGE Australia 
thermometer 303K Levell 
ultracentrifuge TL-400 Beckmann 
UV analytical plate reader Molecular Devices Corporation 
vacuum pump Whatman 
videos AG-6200 Panasonic 
 
 
2.1.3 Microscopes and photodocumentation 
 
microscope/film source of supply 
microscope Axiophot Zeiss 
microscope Diaplan Leitz 
T-MAX 400 (black and white) Kodak 
ectachrome 400 (colour) Kodak 
 
 
2.1.4 Primary Antibodies 
 
antibody specification source dilution 
mouse-anti-tyrosine against tyrosine hydroxylase Boehringer Mannheim 1:50 
hydroxylase of rat, chicken, quail, cow and Prof. H. Rohrer 1:500 
mouse-anti-AChE against globular forms of Tsim et al. 1988 1:100 
mab 3D10 AChE 
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rabbit-anti-AChE polyclonal, against AChE Dr. J. Grassi 1:50 
 
 
2.1.5 Secondary Antibodies and detectionsystems 
 
antibody source dilution 
sheep-anti-mouse Ig-Biotin Amersham, 1:100 
donkey-anti-rabbit Ig-Biotin Amersham 1:100 
goat-anti-rabbit-DTAF dianova 1:100 
streptavidin-texas red Amersham, 1:100 
avidin-peroxidase Sigma 1:100 
Vector SG substrate kit for peroxidase Vector Laboratories, USA 
Vector VIP substrate kit for peroxidase Vector Laboratories, USA 
 
 
 
2.1.6 On-line chemiluminescent technique reagents 
 
ACSF and all stock buffer solutions were made up monthly and stored at 4°C, and all other 
reagents used were made up just for the very day of the experiment. In all cases the solutions 
are made using de-ionised water. The chemicals used in the chemiluminescent assay were all 
purchased from Sigma Chemical Co., UK. 
 
2.1.6.1 Artificial cerebrospinal fluid (NaCSF) stock solution (1litre) 
 
NaCl 14.900g (255 mM) 
KCl   0.444g (6 mM) 
NaHCO3   3.108g (37 mM) 
KH2PO4   0.156g (1 mM) 
Na2HPO4   0.142g (1 mM) 
In order to make up 100 mls of the diluted solution, the following solutions compounds and 
solutions were mixed: 
NaCSF stock 50 ml 
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De-ionised H2O 30 ml 
CaCl2 (26 mM) 10 ml 
MgCl2 (8 mM) 10 ml 
Glucose 90 mg 
ACSF were always bubbled with 95% O2 and 5% CO2 before being used and during the hole 
experiment, this ensured that the correct pH was obtained. 
 
2.1.6.2 Additional buffers 
 
Each of the following buffer solutions were made up to 200 mls with de-ionised water. 
Borax/EDTA buffer solution: 
Borax 3.814g (50 mM) 
EDTA 1.1167g (15 mM) 
 
TRIS/EDTA buffer solution: 
TRIS HCl 2.422g (100 mM) 
EDTA 1.1167g (15 mM) 
 
2.1.6.3 Chemiluminescent reaction reagents 
 
Choline oxidase 100U vial was prepared by the addition of 2 ml of de-ionised water to each 
vial, mixing the resultant solution, and decanting out into either 0.4 ml or 0.8 ml aliquots into 
eppendorfs, which were then frozen at -20°C. On the day of the experiment, 1.6 ml of choline 
oxidase was defrostet and mixed with 6 ml of TRIS/EDTA buffer. 
 
Acetylcholine chloride 150 mg vial was prepared on the day of experimentation by the 
addition of 125 ml of de-ionised water to one vial, mixing the resultant solution and altering 
the pH to pH 4.0 using 1 M hydrochloric acid. 
 
Microperoxidase stock 10 mg vial was prepared by the addition of 1 ml of de-ionised water to 
each vial, mixing the resultant solution and decanting it out into 80 µl aliquots in eppendorts, 
which were the frozen at -20°C. 
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Horseradish Peroxidase stock was prepared by weighing out 40 mg of powder, to which was 
added 4 ml of de-ionised water. The resultant mixture was then mixed using a stirrer and 800 
µl aliquots of the solution were decanted into eppendorfs. Any aliqute not intended for 
immediate use were frozen at -20°C. 
 
Luminol/Peroxidase mixture was prepared on the day of experimentation. It contains 20 mg of 
luminol dissolved in 0.8 ml of 1 M NaOH. After ensuring that all the luminol had dissolved, 
20 ml BORAX/EDTA buffer, 80 µl of microperoxidase stock and 800 µl of horseradish 
peroxidase stock were all added to this solution. After using a stirrer to mix these reagents, the 
pH of the resultant mixture was adjust to pH 11.4 using 5 M NaOH. 
 
Acetylcholinesterase 500 U vial in order to prepare a stock solution (100 mU), 5 ml of de-
ionised water was added to each vial and the solution was mixed. The resultant mixture was 
then decanted out into 0.5 ml aliquots in eppendorfs, which were then frozen at -20°C. On the 
day of the assay, in order to obtain a calibration plot, one aliquote was defrosted and serially 
diluted with ACSF, to achieve activities of 1, 2, 5 and10 mU/ml: where 1U of AChE will 
hydrolyse 1 µmol of acetylcholine per minute at pH 8 and 37°C. 
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Acetylcholine 
      ↓ Acetylcholinesterase 
Choline + Acetate 
      ↓ Choline oxidase 
H2O2 + Betaine 
    Luminol ↓ Microperoxidase 
      ↓ Horseradish Peroxidase 
Light Production 
(optimal: pH 8.4, 20oC) 
 
Figure 1 The chemiluminescent reaction used, to measure the release of AChE release from 
the substantia nigra of freely moving rats. 
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2.1.7 HPLC reagents 
 
2.1.7.1 HPLC mobile phase 
 
Citric Acid 15.760 g 
KH2PO4 23.700 g 
Octane Sulphonic Acid 2.340 g 
EDTA 0.372 g 
Make up about 5 litres. The pH of this mixture was adjusted to between 3.59-3.60 and 5 M 
NaOH was used. Once the correct pH was achieved, 15% of the volume was removed (750 ml 
in 5 litres) and replaced with methanol (HPLC Grade). Before it being used, de-gas mobile 
phase. 
 
2.1.7.2 Additional buffers 
 
Each of the following buffer solutions were made up to 100 mls with de-ionised water. 
TRIS buffer solution (3 M, pH 8.6): 
TRIS BASE 27.90g (2.3 M) 
TRIS HCl 10.98g (0.7 M) 
Boric/Citric Acid: 
Boric Acid 1.5458g (0.250 mM) 
Citric Acid 2.6260g (0.125 mM) 
 
2.1.7.3 GSH/EDTA/HClO4-solution 
 
EDTA 80 mgs 
perchloric acid 0.43 mls 
de-ionesed water 5 mls 
glutathione 24.6 mgs 
make up to 50 mls with de-ionesed water. 
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2.1.7.4 Standards 
 
α-Methyl Dopa 21.12 mg/10 mls of mobile phase is 10-2 M 
Dopamine 18.96 mg/10 mls of mobile phase is 10-2 M 
Dopac 16.81 mg/10 mls of mobile phase is 10-2 M 
 
 
2.1.8 Equithesin 
 
Sagatal 40.5 ml 
MgSO4 5.3 g 
Ethanol 25 ml 
Chloralhydrate 10.5 g 
Propylene Glycol 99 ml 
make up to 250 ml with distilled water, stir well. 
 
 
2.1.9 6-Hydroxydopamine 
 
Weight out 0.0080 g 6-Hydroxydopamine and 0.0040 g ascorbic acid in eppy, dissolve with 1 
ml sterile saline. Store in dark and on ice. 
 
 
2.1.10 Drugs 
 
2.1.10.1 Amphetamine 
 
Weight out 0.0184 g amphetamine and dissolve in 5 ml ACSF = 10-2 M. 
Dillute each time 0.5 ml of the higher amphetamine solution with 4.5 ml ACSF to get 
different concentrations: 
0.5 ml (10-2 M)) + 4.5 ml ACSF = 5 ml 10-3 M 
0.5 ml (10-3 M)) + 4.5 ml ACSF = 5 ml 10-4 M 
0.5 ml (10-4 M)) + 4.5 ml ACSF = 5 ml 10-5 M 
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0.5 ml (10-5 M)) + 4.5 ml ACSF = 5 ml 10-6 M 
0.5 ml (10-6 M)) + 4.5 ml ACSF = 5 ml 10-7 M 
For 1 mg amphetamine/kg bodyweigh(e.g. 0.3mg/300g) dissolve 2 mg amphetamine in 4 ml 
saline (e.g. 0.6 ml/300g). 
 
2.1.10.2 Apomorphine 
 
Weight out 0.01519 g apomorphine and dissolve in 5 ml ACSF = 10-2 M. 
Dillute each time 0.5 ml of the higher apomorphine solution with 4.5 ml ACSF to get different 
concentrations: 
0.5 ml (10-2 M)) + 4.5 ml ACSF = 5 ml 10-3 M 
0.5 ml (10-3 M)) + 4.5 ml ACSF = 5 ml 10-4 M 
0.5 ml (10-4 M)) + 4.5 ml ACSF = 5 ml 10-5 M 
0.5 ml (10-5 M)) + 4.5 ml ACSF = 5 ml 10-6 M 
0.5 ml (10-6 M)) + 4.5 ml ACSF = 5 ml 10-7 M 
For 1 mg apomorphine/kg bodyweigh + 0.2 mg ascorbic acid/kg bodyweigh dissolve 2 mg 
apomorphine + 0.4 mg ascorbic acid in 4 ml saline. 
 
2.1.10.3 Quinpirole 
 
Weight out 0.0128 g quinpirole and dissolve in 5 ml ACSF = 10-2 M. 
Dillute each time 0.5 ml of the higher quinpirole solution with 4.5 ml ACSF to get different 
concentrations: 
0.5 ml (10-2 M)) + 4.5 ml ACSF = 5 ml 10-3 M 
0.5 ml (10-3 M)) + 4.5 ml ACSF = 5 ml 10-4 M 
0.5 ml (10-4 M)) + 4.5 ml ACSF = 5 ml 10-5 M 
0.5 ml (10-5 M)) + 4.5 ml ACSF = 5 ml 10-6 M 
0.5 ml (10-6 M)) + 4.5 ml ACSF = 5 ml 10-7 M 
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2.1.10.4 NMDA 
 
Weight out NMDA and dissolve in 5 ml ACSF = 10-2 M. 
Dillute each time 0.5 ml of the higher NMDA solution with 4.5 ml ACSF to get different 
concentrations: 
0.5 ml (10-2 M)) + 4.5 ml ACSF = 5 ml 10-3 M 
0.5 ml (10-3 M)) + 4.5 ml ACSF = 5 ml 10-4 M 
0.5 ml (10-4 M)) + 4.5 ml ACSF = 5 ml 10-5 M 
0.5 ml (10-5 M)) + 4.5 ml ACSF = 5 ml 10-6 M 
0.5 ml (10-6 M)) + 4.5 ml ACSF = 5 ml 10-7 M 
 
2.1.11 Ellman reagents 
 
Make up 0.1 M KH2PO4 buffer pH 7. 
Dissolve 31.7 mg 5,5’-dithio-bis(2-nitrobenzoic acid) and 12 mg sodium hydrogen carbonate 
together in 10 ml of the stock buffer (DTNB solution). 
Dissolve 28.9 mg acetylthiocholine iodide in 10 ml of distilled water (ATC solution). 
To make Ellman’s reagent mix the KH2PO4 buffer, DTNB solution and ATC solution at a 
ratio of 5:1:1. 
 
 
2.1.12 Lowry reagents 
 
Dissolve 10 mg bovine serum albumin (BSA) in 10 ml of distilled water and make up BSA 
standards: 
µl BSA    + µl H2O = µg/ml BSA 
0  250  0 
10  240  40 
20  230  80 
25  225  100 
50  200  200 
75  175  300 
100  150  400 
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150  100  600 
200  50  800 
250  0  1000 
Make a 1% copper sulphate solution (0.1g/10ml) and a 2% sodium potassium tartrate solution 
(0.2g/10ml). Mix equal volumes of these two solutions together and then add 1 ml to 50 ml 
2% sodium carbonate/0.4% sodium hydroxide solution (2g and 0.4 g/100 ml respectively). 
Dilut 2 N Folin-Ciocalteu’s phenol reagent 1:1 with distilled water. 
 
 
2.1.13 Culture medium 
 
Mediums were stored at 4oC, supplements at -20oC. The culture medium was made up freshly 
and stored at 4oC. 
Mediums: 174.00 ml DMEM 
  174.00 ml F12 
Supplements:  40.00 ml FCS (10%) 
    8.00 ml CS (2%) 
    4.00 ml L-glutamine (1%) 
    0.40 ml penicillin/streptomycin (0.1%) 
    0.15 ml gentamycine (0.02mg/ml) 
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2.2 Methods 
 
 
2.2.1 Experimental animals 
 
Male Wistar rats, weighing 200-250g were bought from OLAC, Harlan UK Limited, Shaw’s 
Farm, Blackthorn, Bicester, Oxon, OX6 0TP. The animals were housed under standard 
conditions and fed with laboratory food. Chick embryos where also used, the given stages of 
development refer to the incubating time in days. Fertilized white Leghorn chicken eggs 
(Gallus gallus domesticus) were purchased from LSL-Rhein-Main (Geflügel-
vermehrungsbetrieb GmbH, Dieburg). Until incubating the eggs were stored at 4°C. Brooding 
took place in an incubator at 37.8°C. The eggs were rotated automatically every 30 min. 
Atmospheric humidity was 92%. 
 
 
2.2.2 Construction of push-pull cannulae 
 
Required materials: Microlance 3 sterile 22G 0.8X40 No2 T.W.P.M. Becton Dickson Dublin 
or Hypo needle tubing 22G 10-22gX30 cm S/S tubing, PVC Manifold Tubing Altec Alton 
Hampshire, Ento Pins 38X40 mm Asta Tipton, Araldite Rapid R2 Giba-Geigy Plastics 
Duxford Cambridge. 
Push-pull cannulae were constructed from two concentric stainless-steel tubes (22 
gauge,Microlance 3 or S/S Hypo needle tubing). An angled hole was filed out about half way 
along one side of one the tubes and a smaller length of tube (with one of its tips also filed) 
was fitted to it to make a `Y’ shape (figure 2 A). The tubes were kept in place using vinyl 
tubing (1 mm internal diameter, PVC Manifold) and this was then sealed with araldite glue. 
The main shaft of the external cannula was kept patent by using an obdurator constructed 
from a 0.35 mm gauge insect pin (Ento Pin) which completely filled the bore and protruded 
about 0.5 mm from the bottom end of the cannula and prevent tissue blocking when the 
cannula is implanted. In all cases the cannula was made as small as possible to minimise the 
exposed area of the cannula above the skull and do reduce accidental shifting of the cannula 
during the housing and experimentation periods. 
 
Materials and Methods 28
Required materials: Pin needle tubing, PVC Manifold Tubing Altec Alton Hampshire, 
Araldite Rapid R2 Giba-Geigy Plastics Duxford Cambridge. 
An inner cannula was constructed using 31 gauge stainless-steel tubing (pin needle Tubing) 
and designed so as to protrude about 0.5 mm from the bottom of the vertical shaft of `Y’ 
shaped cannula (figure 2B). The Hypo needle Tubing was held in PVC Manifold Tubing (0.1 
mm internal diameter). In order for an air tight seal to be formed between the inner and outer 
cannulae, the 31 gauge tubing was threaded through Manifold Tubing 1.0 mm internal 
diameter and the construction supported by Manifold Tubing with an 2.0 mm internal 
diameter, this stucture was held together using araldite. Prior to experimentation the obdurator 
was removed and replaced by the inner cannula, which was connected to a continuous flow of 
ACSF. 
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(A)  
(B)  
 
Figure 2 Schematic diagram of the push-pull cannula used in this thesis (not to scale). The 
outer/pull cannula (A) was constructed from two concentric stainless steel tubes (22 gg) filed 
exactly to fit together in a Y-shape, this structure was then held in place using PVC Manifold 
tubing and araldite. An obdurator (0.35 mm gauge ento pin) completely filled the bore and 
protruded about 0.5 mm from the bottom end of the cannula. The inner/push cannula (B) was 
constructed using 31 gauge Hypo needle tubing held in PVC Manifold tubing (0.1 mm 
internal diameter) and designed so as to protrude to the same depth as the obdurator from the 
bottom of the vertical shaft of outer cannula. 
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2.2.3 Surgical procedure: implantation of push-pull cannula 
 
Male Wistar rats, weighing 250-280g, were anaesthetised with Equithesin, 2 ml/kg (Hawkins 
and Greenfield, 1992a). This dosage produced a state of surgical anaesthesia for up to one 
hour. Following the establishment of deep anaesthesia, determined by an absence of a corneal 
and knee jerk reflexes, the hair on animal’s head was shaved and the animal’s head was fixed 
into a stereotaxic frame by ear bars and an incisor bar. When the animal was correctly 
positioned in the stereotaxic frame, an incision was made in the midline of the head to expose 
the skull and the periosteum pushed to side of the cranium. The head was levelled horizontally 
at the pionts bregma and lambda on the surface of the animals skull. A push-pull cannula was 
implanted unilaterally into the left or right substantia nigra at stereotaxic co-ordinates 
(modified from Paxinos and Watson, 1982): 5.3 mm anterio to bregma; 2.0 mm lateral or 
dorsal to the midline, and 8.0 mm below the skull. The exact position of the substantia nigra 
was marked on the animal’s skull and a small hole drilled through the bone at this position. 
Four bone screws, implanted in a square pattern around the hole, are then carefully screwed 
into the skull around the proposed cannula site ; a square pattern is formed with the screws, 
which will provide a support structure for the dental cement (Astenal Dental Products) applied 
later. The dura mater was then carefully retracted using a needle tip and the cannula was 
lowered to the appropriate co-ordinates. While the cannula was still attached to the stereotaxic 
frame, dental cement was moulded around the base of the cannula and moulded into a crude 
cube shape supported by the four screws. Prior to detaching the cannula from the frame, a 
light emitting diode (LED) was implanted into the dental cement, for use with the ANTRAK 
system. When surgery was completed, a tetracycline-containing antibacterial powder 
(teramycin) was sprinkled in and around the existing cut on the animals head, in order to 
minimise any infection of this site. The animal was kept warm under a heat lamp until it had 
fully recovered from the anaesthetic. Each surgery-treated animal was then housed separately 
to minimise damage to the cannula-containing structure and allowed a minimum of 48 hours 
to recover from surgery, prior to the experiment. Food and water were available ad libitum. 
Again all surgically-operated animals were housed separately, unfortunately, it soon became 
apparent that the rats were knocking their cannula on the slanting roofs of these cages and thus 
an adaptation to existing rat-holding cages was required. By attaching a sheet of stainless steel 
(North Kent Plastics) to the base of the food tray, the animal cannot any longer enter the void 
space. Therefore, the chances of the animal damaging its cannula are decreased. 
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2.2.4 Surgical procedure: neurotoxintreatment 
 
Male Wistar rats, weighing 250-280g, were anaesthetised with Equithesin, 2 ml/kg (Hawkins 
and Greenfield, 1992a). This dosage produced a state of surgical anaesthesia for up to one 
houre. Following the establishment of deep anaesthesia, determined by an absence of a 
corneal and knee jerk reflexes, the hair on animal’s head was shaved and the animal’s head 
was fixed into a stereotaxic frame by ear bars and an incisor bar. When the animal was 
correctly positioned in the stereotaxic frame, an incision was made in the midline of the head 
to expose the skull and the periosteum pushed to side of the cranium. The head was levelled 
horizontally at the pionts bregma and lambda on the surface of the animals skull. A fine-gauge 
needle was lowered stereotaxically into the medial forebrain bundle at coordinates 3.8 mm 
anterio to bregma, 1.8 mm lateral to the midline and 9.0 mm below the skull according to the 
atlas of Paxinos and Watson (Paxinos and Watson, 1982). The 6-OHDA was made up fresh 
on the day of use, in a concentration of 8 mg/ml in ascorbic acid 4 mg/ml in sterile saline and 
kept in ice. This solution was delivered from a Hamilton microsyringe (10 µl) via the fine 
needle at a rate of 0.25 µl/min for 4 mins (1.0µl of neurotoxinsolution), i.e. a total of 8 µg 6-
OHDA was injected into the medial forebrain bundle. Following the injection the needle was 
kept in place for 2 mins to allow the neurotoxinsolution to diffuse from the needle tip into the 
surrounding tissue, then removed from the brain. The animals were left for at least 3 weeks for 
the degeneration to become complete. Another group of rats were sham-operated, i.e. 
subjected to the surgical procedure described above, but receiving a micro-infusion of sterile 
saline (9% v/w) with ascorbic acid only. After neurotoxin treatment the push-pull cannula was 
implanted unilaterally into the unlesioned substantia nigra as described above and a LED was 
implanted into the dental cement. 
 
 
2.2.5 Perfusion via push-pull cannula 
 
The substantia nigra was perfused with artificial cerebrospinal fluid (ACSF) at 37°C, gassed 
with 95% O2, 5% CO2, at a flow rat of 20 µl/ml. The ACSF contained (in mM): NaCl, 127; 
KCl, 3; NaHCO3, 18.5; KH2PO4, 0.6; Na2HPO4, 0.5; CaCl2, 2.5; MgCl2, 0.8 and d-glucose, 5. 
A stock solution of d-amphetamine-sulphate (10-2 M) (generous gift of Chris Webb, Oxford), 
quinpirole (10-2 M) (RBI, USA) and NMDA (10-2 M) (generous gift of Dr. S. Cragg, Oxford) 
Materials and Methods 32
was prepared in ACSF and diluted accordingly in ACSF prior to its introduction into the 
system. D-amphetamine, quinpirole and NMDA (10-7 M, 10-6 M, 10-5 M, 10-4 M, 10-3 M, 10-2 
M) was introduced for 5 min periods to the substantia nigra via the cannula and a 15 min 
recovery period was allowed between consecutive applications. 
 
 
2.2.6 Flow circuit 
 
A diagrammatic representation of the flow circuit used in this technique is illustrated in figure 
3. In order to produce a continuous flow of ACSF into and out of the substantia nigra, 
Manifold and non-Manifold vinyl tubing (internal diameter between 0.15 and 0.5 mm) 
connected to Gilson `Minipuls 2´ peristaltic pumps was used in this circuit. Using a solenoid 
device, air bubbles were introduced into the flow of choline oxidase at a steady rate (every 5 
seconds), see figure 4. Regularly spaced bubbles were introduced into the system in an attempt 
to restrict lateral diffusion of the AChE present in the ACSF perfusate. The closest site of 
integration of the bubbles into the flow of the perfusate was at the t-junction where the 
perfusate meets the flow of choline oxidase solution. Acetylcholine joined the mean stream 
just before the stream entered a cooled incubator. The two enzymatic cascades were 
completed at this point, and hydrogen peroxide was produced and preserved within this 
incubator. On entering the light cell, the hydrogen peroxide reacts with the cocktail of 
peroxidase enzymes and luminol, resulting in the oxidation of luminol, the emission of 
photons and hence the production of light. 
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Figure 3 Schematic diagramm of the on-line circuit without an animal attached. Thick lines 
symbolize PVC Manifold tubs, arrows indicate direction of flow and numbers show flow rates 
(µl/minute). Exogenous AChE, diluted in ACSF, was introduced into the system via 
peristaltic pump (PP) 1 and pumped via the swivel head-piece to the light reaction chamber 
along with the reagents necessary for the chemiluminescent reaction. The light-derived signal 
was then displaced on an oscilloscope and chart recorder and recorded onto a video tape. 
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Figure 4 The injection system for introducing air bubbles into the flow of choline oxidase at a 
steady rate and at a low temperature (0 to 4oC) consisting a solenoid device and a case to store 
ice. 
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2.2.7 Light cell and luminometer 
 
Required materials: Microlance 2 21G 0.8X40, Pin needle tubing 31G, Borosilicate Glass 
Capillars 1.4mm 4IN WPI Sarasota USA, PVC Manifold tubs, Araldite rapid Giba-Geigy. 
The `light-cell´ reaction chamber was constructed from 21 and 31 gauge stainless steel tubing 
and a glass microtube (figure 5 A). In a section of 21 gauge tubing (about 30 mm in length) a 
small hole was filed out of the side of the tubing (about half way along). Through this hole, 
and thus through the lumen of the 21 gauge tubing, the 31 gauge was threaded so that it 
protruded about 0.5 mm from the tip of the wider tubing. The two-stainless steel tubes 
construction was then threaded into a thin glass microtube (internal diameter 1.5 mm) up to 
the filed hole and the structures were sealed using araldite.This structure was mounted in the 
luminometer in front of the photomultiplier tube and just behind a mirror positioned to reflect 
the light produced from the chemiluminescent reaction, back onto the photomultiplier tube 
(figure 5 B). The luminol/peroxidase mixture enters the chamber through the fine stainless 
steel tubing (31 gauge), while the perfusate/other reagents required for the reaction enter 
through the wider tubing (21 gauge). The chemiluminescent reaction occurs just above the 
protruding end of the thinner stainless steel tubing and is monitored by the photomultiplier 
tube. The reaction has to occur in the glass tube, not in a perspex tube, to avoid a loss of 
signal. 
Materials and Methods 36
 
 
(A) 
 
(B) 
 
Figure 5 Diagrammatic representation of (A) the light cell reaction chamber, consisting of 21 
and 31 gauge stainless steel tubs into a glass micotube. Figure (B) demonstrates the location 
of the light cell within the luminometer. The light cell reaction chamber was positioned 
immediately in front of the photomultiplier tube and a small mirror was mounted behind the 
light cell reaction chamber. The luminol/peroxidase solution entered the chamber through the 
thinner stainless steel tube and the ACSF solution containing hydrogen peroxide entered into 
the chamber via the wider stainless steel tube. 
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2.2.8 Calibration plot of actylcholinesterase activity 
 
Prior to the start of each experiment a calibration plot of AChE activity was carried out to 
allow quantification of AChE released from the substantia nigra of the rat during the course of 
the experiment (see figure 6 A, B, C). Firstly, the system needs to be calibrated to insure the 
flow of ACSF into the system was equal to the removal of ACSF from the system. Connection 
of a Hamilton syringe, modified, so that it could be connected to the Manifolds vinyl tubing, 
to the system at the inflow and outflow tubing arround the swivel head piece (rotation-
adapter), to allow the liquid flow in the tubing to be calibrated. This syringe can then be used 
to equalise the flow rates at 20 µl/min. Minor adjustment to the speed of the perfusion pumps 
was made until the meniscus in the Hamilton syringe remained stationary and therefore the 
flow rates were equal. 
Once the inflow and outflow tubes were equalised, exogenous AChE(Sigma, Electric eel type 
VI-S), diluted accordingly with ACSF to activities of 1, 2, 5, 10 mU/ml, was added to the 
system (figure 6 A). Each sample was added to the system via outflow tube on the swivel into 
the flow of the choline oxidase solution (figure 3) for three minutes and then followed by a 
five minute period of ACSF. Since this system was based on an ex situ measurement of the 
activity of AChE released from the substantia nigra, a time delay occurs between the addition 
of the AChE sample and the resultant chemiluminescent reaction (usually about 15 minutes). 
In order to calculate the time delay between sample application and chemiluminescent 
reaction, the end of the input tube was transferred from ACSF solution to ACSF solution 
containing AChE, and the exact time of the start of the appearance of the corresponding signal 
was noted. Thus, by carrying out a calibration plot on a daily basis, the exact time delay of the 
perfusate leaving the substantia nigra to it reaching the light cell can be calculated. 
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Figure 6 Typical plot of decreasing concentrations of exogenous AChE in mU/ml (Sigma, 
Electric eel type VI-S), added to the system prior to attachment on animal; absolute 
concentration mU, in brackets. Samples are added to the system for three minutes and then a 
period of five minutes of ACSF follows prior to the addition of the next sample. (B) Data got 
for example used in this thesis and (C) the calibration plot of exogenous AChE of this data. 
The areas under the various concentration curves were measured using a oscilloscope. Only 
the middle two minutes of the area under the curve were measured. 
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2.2.9 Connection of the animal to the system 
 
Upon completion of the calibration plot, the animal under investigation was incorporated into 
the system, as shown in figure 7, and the perfusion of the substantia nigra commenced. ACSF 
was perfused into the substantia nigra through the inner cannula and removed through the side 
arm of the wider outer cannula (see figure 2 A, B). The perfusate was incorporated into the 
main flow circuit into the path of the flow of choline oxidase solution. A large signal peak 
was always obtained at the beginning of each infusion due to blood contamination/air when 
connecting the outflow tube to the side arm of the cannula. Thus, the signal should always be 
allowed to reach a constant/steady baseline value before any further experiments are carried 
out. Rats are quiet agile and active creatures compared to other experimental animals, e.g. 
guinea-pigs. This often led to entanglement of the inflow and outflow tubes connected to the 
cannula structure and necessitated detachment of the cannula from the tubing used in this 
system and thus unnecessary distress to the handler and animal. To overcome this problem a 
swivel head-piece was used (see figure 8).This swivel head-piece is clamped above the arena 
and the inflow and outflow tubes are attached to horizontal endports. Additional Manifold 
vinyl tubes can then be attached to the corresponding vertical endports, so as to create a 
continuous inflow - outflow system. The advantage of this system is that the Manifold vinyl 
tubes attached to the vertical endports can be threaded through the hollow cylindrical structure 
attached to the swivel head-piece and thus will never tangle. The animal is now free to move 
without any chance of entanglement of the inflow and outflow tubing. 
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Figure 7 Diagrammatic representation of the chemiluminescent assay circuit for measuring 
endogenous release of AChE from the rat substantia nigra. Arrows indicate direction of flow 
and numbers show flow rate (µl/min) at points throughout the circuit. AChE secreted into the 
perfusate bathing the substantia nigra was delivered via peristaltic pump (PP) 1 to the light 
reaction chamber along with reagents necessary for the chemiluminescent reaction. The 
perfusate was continuously analysed ex situ and thus the signal occurs off-line (i.e. lagging 
approximately 15 minutes behind the event). The use of video analysis permits 
resynchronization of the signal trace, allowing the system to become essentially on-line. Thus 
any change in animal behaviour possibly related to AChE release can be determined. 
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Figure 8 Diagrammatic representation of the swivel head piece. Rats are quiet agile creatures, 
when they receive drug/stimulatory agents which induce movement it soon becomes apparent 
that this result in problems like entanglement of the inflow and outflow tubes connected to the 
cannula structure. It necessitated detachment of the cannula from the tubing used in this 
system in an attempt to overcome this problem a swivel head piece was used. This swivel was 
clamped above the cage floor and the inflow and the outflow tubes are attached to horizontal 
endports. Additional Manifold tubes can then be attached to the corresponding vertical 
endports, so as to create a continous inflow - outflow system. The Manifold tubes attached to 
the vertical endports can be threaded through the hollow cylindrical structure attached to the 
swivel head piece in order to prevent them from being entangled. 
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2.2.10 Recording of acetylcholinesterase release and movement 
 
The equipment used to monitor the continuous endogenous release of AChE and any animal 
movements is shown in figure 9 (A), (B). Light produced from the chemiluminescent reaction 
is first detected by the photomultiplier tube and the resultant signal is amplified and converted 
to a FM signal via frequency modulator. This signal was then recorded onto the audio channel 
of the VHS video recorder 1 and also displayed as a trace on the chart recorder. Two video 
recorders are used in this technique: one to record the FM signal and the video picture, the 
other just the video picture. Therefore, if any interesting observations occur with respect to 
AChE release and movement, the FM signal can be recorded onto the video picture in video 
recorder 2. A video timer can be used to start record the FM signal of one video tape onto the 
video picture of the other video tape, in order to give a FM signal/video picture in `real time´; 
thus the lag-time between release of enzyme and its detection is accounted for. The system 
now allows for the release of AChE to be observed in `real time´ with respect to movement. 
Materials and Methods 43
 
 
 
 
 
 
 
 
 
(A) 
Materials and Methods 44
 
 
 
 
 
(B) 
Materials and Methods 45
Figure 9 Equipment used in the detection of in vivo AChE release from the substantia nigra 
and any animal movements. (A) photograph showing the equipment; 1. FM modulator/ 
demodulator circuit used to interconvert the voltage form of the AChE-derived light signal 
into an FM form (which could then be recorded onto video tape 2), 2. video recorder 2 used to 
record the AChE-derived light signal, 3. video timer used, ultimately, to allow the behaviour 
of the animal and the on-line signal of AChE release within the substantia nigra to be 
synchronized, 4. current-to-voltage converter and amplifier used to amplify and convert the 
current output signal of the photomultiplier tube into a voltage form, 5. video recorder 1 used 
to record the behaviour of the animal, 6. RM Nimbus computer used to analyse with the help 
of the Antrak-video based animal tracking system the behaviour of the animal, 7. needle 
printer used to print out the computer plotted picture of animal behaviour analysed with the 
Antrak system, 8. chartrecorder used to print out continual during the experiment the AChE 
release trace, 9. video monitor used to visualize the behaviour of the animal, 10. video camera 
used to monitor the behaviour of the animal during the experiment, 11. swivel head piece used 
to prevent entanglement of the tubes, 12. LED (light emitting diode) used to detect the 
animals behaviour in conjunction with the Antrak system, 13. housing box of the animal, 14. 
oscilloscope used to visualize the trace of AChE released, 14. luminometer containing the PM 
tube used to detect the light from the chemiluminescent reaction, 15. high voltage power 
supply unit for the PM, 16. hoteplate/thermometer used to controll the temperatur of ACSF, 
17. relay controller for the solenoid used to indruce air bubbles into the main stream of the 
chemiluminescent assay flow circuit. (B) diagrammatic representation of the epuipment. 
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2.2.11 Determination of animal movement 
 
Spontaneous or induced animal movements during the perfusion period, were monitored in 
addition to the video tape using an Antrak-video based animal tracking system (B. Reece 
Scientific Ltd., Newbury, UK), which was used in conjunction with the `on-line´ 
chemiluminescent technique. This system involves computerised tracking of a LED in and 
around a pre-set area within the study arena. The computer then plotted the animals 
movements within a pre-determined time period. It quantifies how far the animal moves and 
how long it spends in any area it has visited (figure 10). The animals movement were also 
count as a number of 360° turns. Animal rotation was measured as the number of 360° turns 
and using the Antrak-video based animal tracking system, motor activity was measured in 
terms of total distance moved. 
 
 
 
 
 
Figure 10 Animal movement monitored with an Antrak-video based animal tracking system, 
computer plotted picture. 
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2.2.12 Analysis of actylcholinesterase release in association with movement 
 
Using the calibration plot carried out at the start of each experiment, the activity of AChE 
released from the substantia nigra can be quantified. The areas under the various concentration 
curves were measured using a Gould 420 oscilloscope, which had built-in measuring 
facilities. Although AChE was added to the system for three minutes, only the middle two 
minutes of the area under the curve were measured. This procedure was carried out to ensure 
that the air bubbles, which occur when transferring from ACSF to ACSF containing AChE 
and back again, did not interfere with the data recorded. Although the concentration of 
exogenous AChE applied were in mU/ml, all data is quantified in absolute units (mU). For 
example, if 1 mU/ml was applied to the system for two minutes at a flow rate of 20 µl/min, 
then the absolute activity of AChE = 0.04 mU (1mU/ml x 2 minutes x 20/1000 ml/minute). 
This permits a calibration plot of absolute activity (mU) versus the area under the curve to be 
constructed (figure 6 A, B, C). 
Basal (spontaneous) release of AChE (in the absence of any drug) was calculated by taking 
three baseline readings and expressing the middle value as a percentage of the other two. 
Evoked release of AChE (following the application of drug) was similarly calculated, relative 
to a period immediately preceding and following the effect of the drug. In general, basal 
release and drug-evoked release of AChE in the substantia nigra were measured for a two 
minute perriod at the centre of each trace, in order to ensure continuity for data analysis. Basal 
release of AChE in both regions were expressed as mU of AChE activity (where 1 U of AChE 
will hydrolyse 1 µmole of acetylcholine per minute at pH 8 and 37°C), whereas the drug-
evoked release of AChE were expressed as a percentage of the spontaneous release of AChE. 
Actual numbers of animals used in analysis are given in the respective figure legends. Some 
animals were not included in the final analysis due to technical problems, e.g. blocked push-
pull cannula. Data were analysed working with Microsoft Exel using analysis of variance 
followed by paired t-test. All results are given as means + SEM for experiments performed 
upon n animals. Statistical significance of the difference between means was estimated using 
paired t-test. The probability levels interpreted as statistically significant were P<0.001 (***), 
P<0.01 (**), P<0.05 (*). 
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2.2.13 Collection of CSF-samples 
 
By stimulation with 10-3 M and 10-2 M amphetamine another group of animals was AChE 
release determined from 5 mins (200µl) aliquots collected during the experiment and kept on 
ice. AChE activity in perfusate samples obtained from the substantia nigra were determined 
using the Ellman technique (Ellman et al., 1961) and analysed spectrophotometrically. 
 
 
2.2.14 Histology 
 
At the end of each experiment, in order to assess cannula placements, dopamine concentration 
in striata, TH and AChE positive neurons in the substantia nigra, animals were deeply 
anesthetized with halothane (Rhône Mérieux Limited, Harlow Essex, UK) and decapitated. 
The cannula/dental cement structure was removed from the skull, great care was required 
when removing the implant. This was essential as the amount of damage caused by removing 
the cannula must be kept to a minimum to ensure that histological verification of the cannula 
tip was not compromised. The brains were carefully removed and stored in formaldehyde (4% 
v/v in phosphate buffered saline, pH 7.4, 4°C) for at least a week. Following fixation, brains 
were placed in cryoprotective solution (30% sucrose in PBS, pH 7.4) until they sink. 10 µm to 
42 µm sections were cut on a freezing microtome or cryostat and each section was mounted 
on a gelatinisated glass slide and stained in different methods, whichever was appreciated. For 
each animal,prior fixation, both striata were removed and stored in a 0.1 M perchloric acid 
containing 1.6 mM reduced glutathione and 4.3 mM EDTA, prior to HPLC analysis. 
 
 
2.2.15 High performance liquid chromatography and Lowry assay 
 
HPLC is an ideal technique for analysing small molecules (molecular weight <1000). This 
procedure is an accurate and sensitive method of determining the catecholamine release and 
content in any brain region under investigation. The principle of this assay is based on the 
phenomenon of air-oxidation of catecholamine. Catecholamines are oxidised at the hydroxyl 
groups to produce an orthoquinone derivative with the release of two electrons. 
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In HPLC this reaction has been harnessed, i.e. a positive potential is applied to the electrode 
and electrons are transferred to the electrode. The current produced is directly proportional to 
the number of molecules oxidised. The oxidation occurs near the surface of a glassy carbon 
electrode. The potential is applied to the working electrode and maintained (via a reference 
electrode) by passing the required current through the working and auxiliary electrodes; hence 
the name - `three electrode system´. The reference electrode consists of an Ag/AgCl electrode, 
with 3 M KCl electrolyte, and functions to provide a stable potential to which the working 
electrode can be compared. 
The HPLC system used in the current experiments consisted of a reverse-phase mode of 
separating samples. In reverse-phase chromatography, retention of compounds on the column 
is due to hydrophobic reactions between the solute and the hydrocarbaceous stationary phase 
(C18-octa-decyl-sulphate particles bound to a silica surface). The principle is that compounds 
are eluted in order of decreasing polarity/ increasing hydrophobicity, i.e. the greater the 
polarity of the compound, the less time it is retained by the non-polar/hydrophobic surface of 
the column and the quicker it is eluted. It should be noted, however, that care must always be 
taken with the pH of the mobile phase used with an octa-decyl-sulphate/silica stationary 
phase. If the pH of the mobile phase is > 7, the silica dissolves and the column is ruined. 
In order to evaluate the effect of neurotoxin pretreatment described in this thesis on tissue 
dopamine content, an HPLC system was used. Dopamine, DOPAC, noradrenaline, 
dihydroxyphenylalanine (dopa) and α-methyl dopa (internal standard) can be easily extracted 
following the method of Anton and Sayre (1962); this protocol is ideal for the requirements of 
the current studies, as it permits the removal of many unwanted neurochemicals such as 
soluble protein and other neurotransmitters and their metabolites, which normally mask 
desired peaks or interfere with the assay. There is one major drawback of this extraction 
method: the exclusion of homovanillic acid (HVA). Therefore, although dopamine content in 
the tissue under investigation can be accurately calculated, conclusions on dopamine turnover 
are severely limited. 
The protein content of each sample is assayed using the standard Lowry procedure (Lowry et 
al., 1961). This now permits data representation as pmol/mg protein. 
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2.2.15.1 Determination of dopamine content in tissue samples using HPLC 
 
Both striata were removed and stored at -20°C in perchloric acid-glutathione-EDTA solution. 
Dopamine and DOPAC were extracted using the method described by Anton and Sayre 
(1962) with minor modifications. Tissue samples were homogenised in 3 ml ice cold 0.1 M 
perchloric acid containing 1.6 mM reduced glutathione and 4.3 mM EDTA, and then 
centrifuged by 10000g at 4°C for 10 minutes. Two ml of supernatant, containing α-methyl-
DOPA (internal standard: final concentration = 10-8M), was added to 80 mg of alumina 
(Al2O3) and mixed with 2 ml of Tris buffer (pH 8.6). The resulting supernatant was removed 
after 10 minutes of mixing and the alumina washed twice with 2 ml water. Dopamine, 
DOPAC and α-methyl-DOPA were eluted with 400 µl of 0.25 M boric acid and 0.125 M 
citric acid solution. 50 µl aliquots of this solution were injected into the system. 
DOPAC and dopamine were quantified by high performance liquid chromatography (C18 
reverse phase column) with electrochemical detection (Waters 460; Millipore, U.K.) set at 
+700 mV with respect to the Ag/AgCl electrode (Felice et al., 1978). The mobile phase run at 
a flow rate of 2ml/minute. A typical trace showing the 3 peaks measured (figure 11 A) is 
shown below inclusive there area under the curve calculated by ChromJet integrator (figure 11 
B). 
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(A) 
 
PEAKS AREA% RT AREA BC 
1 1.02 0.1 1700 01 
2 0.179 3.57 167 01 
3 39.245 4.09 86668 02 
4 0.229 4.73 214 02 
5 18.481 5.05 17265 08 
6 1.115 5.87 1842 05 
7 2.332 6.93 2169 01 
8 0.492 7.7 460 01 
9 0.152 8.65 142 01 
10 0.686 9.76 641 02 
11 0.886 10.21 828 02 
12 0.895 10.38 369 02 
13 0.875 10.51 70 03 
14 0.493 10.73 461 02 
15 2.585 11.88 2368 02 
16 30.894 12.17 28861 03 
TOTAL 100.  93428 
(B) 
 
Figure 11 (A) A typical trace using HPLC showing the peaks measured of α-methyl dopa 
(retention time = 4.09 minutes), DOPAC (retention time = 5.05 minutes) and dopamine 
(retention time = 12.17 minutes). (B) shows the area under the curve calculated with a 
integrator. 
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2.2.15.2 Estimation of protein concentration by Lowry assay 
 
Protein concentrations of the centrifuged pellet were quantified using the method of Lowry et 
al. (1951). The pellet was dissolved in 1ml 1M NaOH. A concentration of bovine serum 
albumin (BSA) standards ranging from 40 µg/ml to 1 mg/ml was required for each assay. This 
was achieved by adding 0-250 µl of 1 mg/ml BSA to individual tubes and adjusting the 
volume to 250 µl with de-ionised water. The protein content of the samples under 
investigation was calculated by diluting between 20-250 µl of the unknown protein solution 
with de-ionised water, ensuring that all solutions were adjusted to 250 µl in each tube. 
Therefore, by comparison of the spectophotometric data obtained from the samples with those 
obtained from BSA standards and accounting for any dilution factors, the protein content of 
unknown samples can be calculated. 
The reagents for the Lowry assay consists of 0.01 % copper sulphate, 0.02 % sodium 
potassium tartrate, 2 % sodium carbonate and 0.4 % sodium hydroxide, made up to volume 
with de-ionised water. One ml of this solution was added to each tube containing unknown 
samples and mixed immediately. Once all the samples had been treated, 100 µl of a 1:1 
dilution of 2 N Folin-Ciocalteu’s reagent (diluted with de-ionised water) was added to each 
tube and again mixed immediately. Finally, after a period of 15 minutes, but not longer than 
two hours, 100 µl aliquots from each tube was added to a microtitre plate and the absorption 
read at 650 nm. Using spectrophotometric data obtained from BSA standard samples, the log 
absorbence is plotted against log standard protein concentration and the protein concentration 
of each sample calculated. 
 
 
2.2.15.3 Analysis of data 
 
Experimental data, obtained by HPLC, was analysed using standard calibration plots obtained 
for dopamine and DOPAC. These calibration plots can be made using standard solutions 
containing varying concentrations of dopamine and DOPAC, ranging from 10-7 to 10-10 M, 
with each sample being spiked with a constant concentration of α-methyl dopa (internal 
standard: final concentration = 10-8 M). 
Dopamine or DOPAC concentration of the standard samples was plotted against: 
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Area under the curve for the dopamine standard  x  Mean peak height of internal standards in that run = 
Peak height of internal standard in that sample 
 
a  x  c 
b 
 
The function a/b was carried out for comparison of the unknown dopamine concentration with 
the known quantity of internal standard; however in order to standardise the results this 
function is then multiplied by `c´. Using the gradient obtained from each calibration plot, the 
concentration of dopamine and DOPAC in unknown sample could be calculated. 
Data obtained from the Lowry assay is analysed using the `SOFTmax´ computer software 
which calculates the protein concentration of the unknown samples from a calibration plot 
derived from a set of protein standard concentrations which are incorporated into the assay at 
the time of running the assay. 
Dopamine and dopac content of both striata obtained from contol and 6-OHDA treated 
animals was expressed as µg/mg protein in the pellet. 
 
 
2.2.16 Determination of acetylcholinesterase activity in CSF samples using the Ellman assay 
 
Rats stimulated local with amphetamine 10-3 M and 10-2 M respectively connected to the `on-
line´ system CSF samples where collected every five minutes in eppendorf cups and kept on 
ice. After collecting the required samples AChE activity was measured immediately using the 
Ellman assay. The Ellman assay (Ellman et al., 1961) is a colour-changing enzymatic reaction, 
which quantifies non-specific cholinesterase activity over a specified time period. The 
substrate acetylthiocholine (ATC) is cleaved by AChE into thiocholine and acetate. The 
sulphydryl group of the thiocholine then reduces the S-S bond of Ellman’s reagent DTNB 
(5,5’-dithio-bis(2-nitrobenzoic acid)), releasing a yellow chromophore (5-thio-2-
nitrobenzoate) which has an absorption maximum near 405 nm and so can be measured in 
microtiter plate reader. The increasing extinction was measured by the aid of a spectrometer 
(UV analytical plate reader) at 405 nm for 10 minutes. This procedure was carried out at room 
temperature (23oC), with the stock solutions at approximately pH 7. 
The 96 micro titer plate were prepared as follows: All samples were assayed in triplicate. 175 
µl of a KH2PO4 solution containing ATC and DTNB was added to 25 µl of CSF contained in 
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cylindrical flat bottomed wells in a microtiter plate. Spontaneous hydrolysis of the substrate 
was corrected by a reagent blank incubated in the absence of enzyme. 
Calculating AChE content: Using a Softmax computer programme (Molecular Devices 
Corporation) the quantity of cholinesterase activity in the sample (Ellman mU/ml) can be 
calculated. Taken the mean vmax value for each sample and multiply by any dilution factor, 
then multiply by 1.026 to give mU/ml. 
 
 
2.2.17 Preparation of embryonic eyes 
 
To get the eyes, chicken embryos of embryonic day (E) 5 to 20 , which ever was required, 
were used. Eggs were stored one hour prior preparation at 4°C. Than the eggshell was opened 
with a curved forceps and the embryo was taken out of the egg, stored into a Petri dish filled 
with PBS and decapitated. After this, the eyes of the embryo were removed with the curved 
forceps and rinsed three times in PBS for 10 mins. 
 
 
2.2.18 Fixation of whole eyes 
 
To keep the structure of the eyes have to be fixated with 4% formalin in PBS overnight at 
4°C. Then the eyes were rinsed three times with PBS and transferred in a solution of 30% 
saccharose and rested at 4°C until they had sunk to the bottom. The saccharose as antifreeze 
protects the tissues against damages from the cryostat procedure. 
 
 
2.2.19 Gelatinisation of microscope slides 
 
Dissolve 5 g gelatine on heat stirrer in 500 ml distilled water and ad 0.3 g chromic potassium 
sulphate, filter and cool. Clean the slides with acid alkohol, 70% alcohol and 1% HCl (350 
mls EtOH + 148 mls dH2O + 2 mls HCl) and rub dry with lint free tissue and place into slide 
racks. Soak slides in 2% Decon, mixed with hot distilled water, over night. Wash slides in 
running tap water for 30 minutes. Than drain and soak in several changes of distilled water. 
Drain and soak in double distilled water. Dip each tray of slides in the cooled gelatin solution, 
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leave there for a few minutes and than drain onto filter paper. Dry racks in 60oC oven over 
night. Remove slides from racks and replace into boxes, label and store at 4oC. 
 
 
2.2.20 Cutting with the cryostat 
 
The box temperatur of the cryostat was about -25°C and the object temperature about -25°C. 
On the object holder of the cryostat a base plate of Tissue-Tek was frozen and later covered 
with a thin layer of saccharose solution. In order to prevent the eyes from cracking up in the 
saccharose solution, it was found necessary also to inject the solution through the fissure into 
the inside of the eye. The eyes were aligned with a forcep, so that the optic fissure rested on 
the base plate and the lens was on the front. The eye was then surrounded with the saccharose 
solution and frozen tightly to the base plate. Then now the 10 µm thin sections were cut. The 
sections were put onto gelatinisated microscope glass slides, which were dried overnight at 
room temperature and stored at -20°C until further use for staining. 
 
 
2.2.21 Cresyl violet staining 
 
Dissolve 1 g cresyl violet acetate in 1l distilled water, heat, while stirring until near boiling 
temperature. Cool. Add 5 ml 10% acetic acid. Slides were hydrated by passing through a 
cascade of solutions of decreasing alcohol content (100-50%), before finally being left in 
distilled water and stained in 1% cresyl violet solution for 30 secondes to 2 minutes. After 
staining slides were washed in distilled water, 70% alcohol and acid alcohol (70% alcohol + 1 
N acetic acid). The stained slides were then dehydrated by passing through a cascade of 
solutions of increasing alcohol content (70-100%), before finally being left for 3 mins in 
xylene. Upon completion of this process the sections were covered with DePex mounting 
medium, onto which coverslips were placed. The slides were then studied under microscope 
to assess cannula tract. 
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2.2.22 Immunocytochemical identification of AChE 
 
Frozen slides were dryed and adapted to room temperature. Then they were treated with 
hydrogen peroxide in methanol to eliminate endogenous peroxidase activity. After icubating 
with Triton X-100, to make the cellmembrane permeable, and FCS, to prevent non-specific 
antibody binding, the sections were incubated with 3D10 (m-α-AChE) or r-α-AChE. After 
this, the sections were incubated with the secondary biotinylated antibody anti-mouse or anti-
rabbit. To detecte the secondary antibody the sections were treated with avidin-peroxidase. 
The last step was the incubation with Vector VIP of SG (including H2O2) to visualise the 
peroxidase and therefore the AChE positive neurons. 
Protocol: 
• frozen slides drying and adapting to RT 
• 3x15 mins washing of the slides with PBS 
• incubating in peroxidase solution (10% methanol, 3% H2O2 in PBS) for at least 30 mins 
• 2x15 mins washing with PBS 
• 1x15 mins washing with PBS with Triton X-100 (1%) 
• incubating in FCS (5% in PBS) for 30 mins 
• transferring of the slides into a wet chamber 
• incubating with primary antibody 3D10 or r-α-AChE (1:100/1:50 in PBS with 1% FCS and 
0.1% Triton X-100) over night at 4°C 
• 2x15 mins washing in PBS 
• 1x15 mins washing in PBS with Triton X-100 (1%) 
• incubating with secondary antibody α-m-Biotin or α-r-biotin (1:100 in PBS with 1% FCS 
and 0.1% Triton X-100) 2h 
• 3x15 mins washing in PBS with Triton X-100 (1%) 
• incubating with avidin-peroxidase (1:70 in PBS) 2h 
• 3x15 mins washing in PBS 
• incubating in Vector VIP or SG for 2 mins 
• 3x15 mins washing in PBS 
• rinsing slides in aqua dest. for 1-2 mins 
• drying slides on heat plate (37oC) 
• covering up with Kaiser’s glyceringelatine 
2.2.23 Immunocytochemical identification of dopaminergic neurons in the substantia nigra 
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Tyrosine hydroxylase (TH) is the rate limiting enzyme of catecholamine synthesis and will 
therefore be present in adrenergic, noradrenergic and dopaminergic neurons. However, 
Decavel et al. (1987) demonstrated, by using a monoclonal antibody against dopamine, that 
the substantia nigra and ventral tegmental area were rich in dopaminergic neurons. Moreover, 
no adrenergic neurons were detected in the substantia nigra by using an antibody to 
noradrenaline (Geffard et al., 1986). Therefore, TH immunoreactivity within the substantia 
nigra is widely accepted as a reliable marker of dopaminergic neurons. 
The brains were fixed in formaldehyde (4% v/v in phosphate buffered saline, pH 7.4, 4°C) for 
at least a week. Following fixation, brains were placed in cryoprotective solution (30% 
sucrose in PBS, pH 7.4) until they sink. 10 µm sections were cut on a freezing microtome and 
each section was mounted on a gelatinisated glass slide and dryed overnight. Then they were 
treated with hydrogen peroxide in methanol to eliminate endogenous peroxidase activity. 
After icubating with Triton X-100, to make the cellmembrane permeable, and FCS, to prevent 
non-specific antibody binding, the sections were incubated with mouse anti-TH antiserum. 
After this, the sections were incubated with the secondary biotinylated antibody anti-mouse. 
To detecte the secondary antibody the sections were treated with avidin-peroxidase. The last 
step was the incubation with Vector VIP of SG (including H2O2) to visualise the peroxidase 
and therefore the TH positive neurons. 
Protocol: 
• frozen slides drying and adapting to RT 
• 3x15 mins washing of the slides with PBS 
• incubating in peroxidase solution (10% methanol, 3% H2O2 in PBS) for at least 30 mins 
• 2x15 mins washing with PBS 
• 1x15 mins washing with PBS with Triton X-100 (1%) 
• incubating in FCS (5% in PBS) for 30 mins 
• transferring of the slides into a wet chamber 
• incubating with primary antibody m-α-TH (1:500 in PBS with 1% FCS and 0.1% Triton X-
100) over night at 4°C 
• 2x15 mins washing in PBS 
• 1x15 mins washing in PBS with Triton X-100 (1%) 
• incubating with secondary antibody α-m-Biotin (1:100 in PBS with 1% FCS and 0.1% 
Triton X-100) 2h 
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• 3x15 mins washing in PBS with Triton X-100 (1%) 
• incubating with avidin-peroxidase (1:70 in PBS) 2h 
• 3x15 mins washing in PBS 
• incubating in Vector VIP or SG for 2 mins 
• 3x15 mins washing in PBS 
• rinsing slides in aqua dest. for 1-2 mins 
• drying slides on heat plate (37oC) 
• covering up with Kaiser’s glyceringelatine 
 
 
2.2.24 Immunocytochemical identification of AChE or/and TH 
 
Frozen slides were dryed and adapted to room temperature. They were then treated with 
Triton X-100, to make the cellmembrane permeable, and FCS, to prevent non-specific 
antibody binding, the sections were incubated with 3D10 (m-α-AChE) or r-α-AChE or m-α-
TH. After this, the sections were incubated with the secondary biotinylated antibody anti-
mouse or anti-rabbit or with the detectionssystem anti-rabbit-DTAF. To detecte the secondary 
antibody respectively AChE/TH positiv neurons the sections were treated with Streptavidin-
Texas Red. 
Protocol: 
• frozen slides drying and adapting to RT 
• 2x15 mins washing of the slides with PBS 
• 1x15 mins washing with PBS with Triton X-100 (1%) 
• incubating in FCS (5% in PBS) for 30 mins 
• transferring of the slides into a wet chamber 
• incubating with primary antibody 3D10 or r-α-AChE m-α-TH (1:100/1:50/1:500 in PBS 
with 1% FCS and 0.1% Triton X-100) over night at 4°C 
• 2x15 mins washing in PBS 
• 1x15 mins washing in PBS with Triton X-100 (1%) 
• incubating with secondary antibody α-m-Biotin or α-r-Biotin (1:100 in PBS with 1% FCS 
and 0.1% Triton X-100) or with the detectionssystem α-r-DTAF 2h 
• 3x15 mins washing in PBS 
• incubating with steptavidin-texas red 2h 
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• 3x15 mins washing in PBS 
• rinsing slides in aqua dest. for 1-2 mins 
• drying slides on heat plate (37oC) 
• covering up with Kaiser’s glyceringelatine 
 
 
2.2.25 Organotypic slice cultures 
 
Cultures were prepared under sterile conditions using a lamina flow hood. All dissecting 
equipment and required materials was sterilised. Solutions that were not obtained pre-
sterilised were passed through a sterile filter. 
Mesencephalon containing the nucleus tegmenti pedunculo pontinus pars compacta (TPc) was 
dissected from E18 old chicks. Throughout the dissection procedure, utmost care was taken in 
order to retain a maximum of histotypic architecture. 
The eggshell was opened and the chick removed and quick decapitated by a scissor cut at the 
level of the foramen magnum. The skull was opened and the brain carfully removed in GBSS 
4oC and placed on the ventral surface on a sterile sartorius filter. The tissue on the filter was 
placed on a McIlwain tissue chopper and coronal sections (200µm) were cut and placed in 
fresh GBSS before being refrigerated for 1.5 hours. Leaving the slices in chilled GBSS for 1.5 
hours allowed proteolytic enzymes to diffuse away from the tissue and for ruptured cell 
membranes to reseal. 
The 200µm mesencephalon slices were attached to cleaned, sterile glass coverslips (diameter 
2cm) by means of a plasma clot formed by mixing a solution of chicken plasma (lyophilised 
chicken plasma reconstituted in 5ml deionized water) with bovine thrombin (0.8mg/ml). The 
tissue section was placed in a 20µl drop of chicken plasma on the coverslip, and a 15µl drop 
of thrombin was then placed adjacent to the plasma drop. The two solutions were gently 
mixed until the plasma/thrombin clot covered the coverslip with the tissue section held in the 
centre. After mounting the sections, the coverslips were refrigerated for 1.5 hours to allow the 
clot to set. 
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Once the plasma clot had set, thus holding the isolated mesencephalon slice in place, the 
coverslip was placed in a culture dish (diameter 35mm). 2ml of serum-containing culture 
medium was then added to each culture dish. The culture dishes were then placed in a 
145mm-culture dish within an incubator (370C, 4% CO2, 70-75 rpm). Between the second and 
fourth day in vitro cytostatic solutions were added for 24 hours to prevent over-proliferation 
of non-neuronal cells. The anti-mitotic substances used were uridine and cytosine-β-D-
arabinofuranoside, both at 10-3 M. Culture medium was changed weekly by carefully suck up 
the old medium and adding 2ml fresh medium. 
 
 
2.2.26 Immunocytochemical identification of dopaminergic neurons 
 
On completion of the incubation period, cultures were fixed and processed for tyrosine 
hydroxylase immunocytochemistry by the biotin-avidin peroxidase method. 
Protocol: 
• cultures were fixed in 4% formaldehyde for 30 mins 
• 3x15 mins washing of the tissue with PBS 
• incubating in peroxidase solution (10% methanol, 3% H2O2 in PBS) for at least 30 mins 
• 2x15 mins washing with PBS 
• 1x15 mins washing with PBS with Triton X-100 (1%) 
• incubating in FCS (5% in PBS) for 30 mins 
• transferring of the coverslip with the tissue into a wet chamber 
• incubating with primary antibody m-α-TH (1:500 in PBS with 1% FCS and 0.1% Triton X-
100) over night at 4°C 
• 2x15 mins washing in PBS 
• 1x15 mins washing in PBS with Triton X-100 (1%) 
• incubating with secondary antibody α-m-Biotin (1:100 in PBS with 1% FCS and 0.1% 
Triton X-100) 2h 
• 3x15 mins washing in PBS with Triton X-100 (1%) 
• incubating with avidin-peroxidase (1:70 in PBS) 2h 
• 3x15 mins washing in PBS 
• incubating in Vector VIP or SG for 2 mins 
• 3x15 mins washing in PBS 
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• rinsing tissue in aqua dest. for 1-2 mins 
• drying coverslips on heat plate (37oC) 
• covering up with Kaiser’s glyceringelatine 
 
Results 62
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
 
RESULTS 
3.1 THE RELEASE OF ACETYLCHOLINESTERASE 
IN THE HEALTHY BASAL GANGLION FOLLOWING 
AMPHETAMINE STIMULATION 
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3 Results 
 
 
A total of 112 animals were used during the `on-line´ study. The number of animals quoted 
initially does not necessarily correspond with the quantity used for statistical analysis, since 
some animals could not be included for technical reasons. For this reason, only the actual 
number of animals used in the analysis is noted in the key to the respective figure. 
 
The placement of nigral cannulae was verified by examination of frozen, cut sections stained 
with cresyl violet. 
 
 
3.1 The release of acetylcholinesterase in the healthy basal ganglion following amphetamine 
stimulation 
 
The first aim of this study was to determine if a relationship exists between AChE-release in 
the substantia nigra and behaviour following amphetamine stimulation in naive animals. 
First of all, I examined the effect which an increase in dopamine levels in the substantia nigra 
and the release of AChE in this region had on the behaviour of naive animals. The objective 
of this study was to determine if a relationship exists between dopamine, the regulation of 
AChE release in the substantia nigra and behaviour. If dopamine and AChE are functionally 
linked, then the enhancement of one may effect the other, as visualised in the behaviour 
patterns observed. 
Figure 12 shows a typical trace of the chemiluminescent signal during different situations. 
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Figure 12: The data trace of a chemiluminescent signal, recorded with an oscillograph. 
The x-axis represents time in seconds, while  the y-axis represents the concentration of the 
AChE in mU/ml, in increments from -4 to 10. During the experiment, the trace was observed 
with an oscilloscope and recorded on the oscillograph. The converter transforms the light 
signals produced by chemiluminescent reactions into electrical impulses. The negative line of 
the trace describes no signal at all. Movement starts at 0 mU/ml AChE at 2000 seconds plus. 
This is a background value produced by the spontaneous disintegration of ACh. All values 
between 0 mU/ml AChE and 2 mU/ml are generated by a discharge of AChE from the 
animal’s brain. These in vivo values are mostly in the region of 2 mU/ml and can be seen as 
basal in trials of this kind. However, if the concentration of AChE rose above normal basal 
levels, this was caused by medication which had been given to the animal a short time earlier. 
This concentration was produced by an increased discharge of enzyme into the CSF. The basal 
values are called 100% values and anything higher is therefore greater than 100%. The results 
can be observed in the following graphs. One thing worthy of note regarding the y axis: 
Calibration of the increments goes up to 10 mU/ml AChE, as this is seen as the highest 
concentration. 
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3.1.1 Amphetamine applied to the `on-line´-system without an animal connected 
 
A stock solution of d-amphetamine-sulphate was prepared in ACSF and diluted accordingly in 
ACSF prior to its introduction into the system. D-amphetamine (10-7 to 10-2 M) was 
introduced for five-minute periods and a fifteen-minute recovery period was allowed between 
consecutive applications. A loss of the chemiluminescent signal was seen at 10-3 M and 10-2 
M (see figure 13). This was also observed when these highest concentrations were tested 
separately (see figure 14). 
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Figure 13: A typical trace showing continuous the chemiluminescent signal produced by the 
spontaneous hydrolysis of ACh in vitro. The first part shows the decreasing concentrations of 
exogenous AChE (Sigma) in mU/ml, added to the system prior to testing the amphetamine 
concentrations 10-7 M to 10-2 M. It shows a loss of the chemiluminescent signal by 10-3 M and 
10-2 M amphetamine. 
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Figure 14: A typical trace showing the chemiluminescent signal produced by the spontaneous 
release of ACh in vitro. The first part shows decreasing concentrations of exogenous AChE 
(Sigma) in mU/ml, added to the system prior to testing the amphetamine concentrations 10-3 
M and 10-2 M. It still shows a loss of the chemiluminescent signal by 10-3 M and 10-2 M 
amphetamine. 
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3.1.2 The basal release of acetylcholinesterase in the rat substantia nigra in vivo 
 
The spontaneous hydrolysis of acetylcholinechloride yielded a signal prior to addition of 
AChE from the rat perfusate. However, subtraction of this background reading allowed the 
basal AChE-perfusate value to be determined. When the cannula was correctly implanted in 
the substantia nigra, a large light-signal was produced, attributable either to blood (in the early 
stage of perfusate extraction), air (when connecting the outflow tubing to the side arm of the 
cannula), or the excess release of AChE (resulting from the animal being handled while being 
connected to the system). Within approximately 20 minutes, this initial increase in the level of 
release gradually dropped to a level that was (in naive rats or sham-operated animals) still 
clearly above the baseline level prior to perfusion (see fig. 5). This signal represented a 
spontaneous release of AChE of 0.25 + 0.07 mU (n=13 local), 0.11 + 0.03 mU (n=9 systemic). 
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Figure 15: A typical trace showing the chemiluminescent signal produced by adding 
decreasing concentrations of exogenous AChE (Sigma) (0-3000 seconds) to the system prior 
to animal attachment. The spontaneous hydrolysis of ACh in vitro is shown as a background 
signal) (3000-6500 seconds). A large signal peak was observed when connecting the animal, 
due to blood/air contamination (6500-8200 sec.). On-line detection of release of AChE in vivo 
can be observed between 8200-11300 seconds. 
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3.1.2.1 Assessment of cannula placement 
 
Animals which had traces of the push-pull cannula outside the substantia nigra and animals 
showing important gliosis were discarded. 
A representative histological section of cannula placement in rats kept for the statistical 
analysis is depicted in figure 16. 
 
 
 
 
 
 
 
 
 
 
Figure 16: A section of the rat brain stained with cresyl violet (width: 42 µm), showing the 
tract of a push-pull cannula ending in the substantia nigra, as marked by an asterisk. 
Stereotaxic co-ordinates are stated in the text. The point marked PR refers to the substantia 
nigra pars reticulata. The point marked PC is the substantia nigra pars compacta. 
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3.1.3 The effect of local administration of amphetamine into the substantia nigra 
 
3.1.3.1 Local administration of amphetamine and its effect on behavioural 
 
Each concentration of amphetamine was infused over a period of five minutes in ACSF. In 
order to directly compare the effects of the different concentrations of amphetamine in the 
substantia nigra, all concentrations were infused under the same conditions: the circling 
behaviour was measured for 15 minutes from the point when amphetamine arrived in the 
substantia nigra to ensure the same conditions for every concentration. A paired t-test 
revealed a significant difference between a very modest basal circling, 0.062 + 0.021 SEM 
turns/min and 10-7 M, 0.22 turns/min + 0.05 SEM, (P<0.05); 10-6 M 0.28 turns/min + 0.09 
SEM (P<0.05); 10-5 M 0.22 turns/min + 0.04 SEM (P<0.01); 10-4 M 0.25 turns/min + 0.05 
SEM (P<0.01); 10-3 M 0.23 turns/min + 0.02 SEM (P<0.001) and 10-2 M 1.11 turns/min + 
0.31 SEM (P<0.01); see figure 17. The most intense circling was seen following 10-2 M 
amphetamine with 3.8 turns per minute. The number of turns per minute observed with this 
concentration are significantly different compared with the lower concentrations ranging from 
10
-7
 M to 10-3 M amphetamine. 
Local infusion of one substantia nigra with amphetamine resulted in a characteristic behaviour 
pattern, see figure 18; the animals often preferred one region of the box, displaying 
contraversive circling and exhibiting a very tight rotation around the axis of their body. 
Amphetamine caused an overall increase in the animal’s activity, and contraversive behaviour 
circling was seen following all amphetamine concentrations. However, a different pattern was 
seen with 10-2 M amphetamine. With 10-2 M amphetamine, a high level of intense circling 
was seen, and, in some cases, animals showed a rapid and persistent shaking of the head. 
Some animals even showed an extreme twisting of the head, touching the rear flank and a 
rapid, continuous movement in one direction. Following amphetamine stimulation, after about 
15 minutes, the circling behaviour and intense general activity ceased. This decline in activity 
coincided with a decrease in the release of AChE. 
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Figure 17: The number of turns per minute exhibited during the 15 minutes following infusion 
of each of the 6 consecutive amphetamine concentrations into the substantia nigra via the 
push-pull cannula, and prior to infusion with ACSF only. Results are expressed as means + 
SEM; asterisks represent a significant difference compared to levels prior to amphetamine; * 
P<0.05, ** P<0.01, *** P<0.001; paired t-test. The number of animals used for each 
concentration was 20. 
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Figure 18: (A) Animal movement prior to infusion with amphetamine, monitored with an 
Antrak video-based animal tracking system. Computer plotted picture, total distance moved: 
771 mm, time elapsed: 120 seconds.  
(B) Animal movement induced by local stimulation with amphetamine (in the substantia nigra 
via the push-pull cannula), monitored with an Antrak video-based animal tracking system. 
Computer plotted picture, total distance moved: 4378 mm, time elapsed: 120 seconds, 
amphetamine dosage: 10-4 M. 
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3.1.3.2 The Local administration of amphetamine and its effect on AchE-release 
 
The spontaneous hydrolysis of acetylcholinechloride yielded a signal prior to addition of 
AChE from the rat perfusate. However, subtraction of this background reading gave a basal 
AChE perfusate value of 0.25 + 0.07 mU (n=13). On stimulating the animals with 
amphetamine (10-7 M to 10-2 M) administered locally to the substantia nigra, there was an 
increase in the level of AChE released (from 10-7 M to 10-4 M) with increasing concentrations 
of amphetamine. Using 10-5 M to 10-4 M, however, the increase in AchE-release reached a 
plateau - see figures 19 and 20. 10-7 M of amphetamine caused a significant enhancement of 
22.87%, P<0.01, in the release of AChE; 10-6 M 35.34%, P<0.01; 10-5 M 32.44%, P<0.05 and 
10-4 M 32.91%, P<0.01. The loss of the signal at 10-3 M and 10-2 M was not attributed to an 
accumulation of the serial amphetamine doses. These highest concentrations were also tested 
separately with and without the animal attached to the system, and a loss of the 
chemiluminescent signal was produced nonetheless. Hence, this reduction in light signal is 
not due to a physiological inhibition of AchE-release, but rather represents a direct chemical 
`quenching´ of the chemiluminescent signal. The same inhibitory effect has been reported 
with 10-6 M 5-HT (5.7-dihydroxytryptamine creatinine sulphate), α-methyl 5-HT (α-
methylserotonin maleate) and 2-methyl 5-HT (2-methylserotonin maleate). 
With a local administration of amphetamine, we were able to see a correlation between AChE 
release in the substantia nigra and behaviour measured in turns per minute - see figure 21. An 
increase in the turns per minute corresponded to a greater release of AChE. A higher 
concentration of amphetamine cannot influence turns per minute but does have an influence 
on AChE-release in the substantia nigra. 
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Figure 19: A typical trace showing the chemiluminescent signal produced by adding 
decreasing concentrations of exogenous AChE (Sigma) to the system prior to animal 
attachment. The spontaneous hydrolysis of ACh in vitro is shown as a background signal. A 
large signal peak was observed when connecting the animal due to blood/air contamination. 
This is followed by an on-line detection of release of AChE in vivo and the intranigral 
stimulation of AChE-release with amphetamine 10-7 M to 10-2 M. 
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Figure 20: The spontaneous release of AChE in the substantia nigra of control and 
amphetamine-treated rats, expressed as a percentage. Results are shown as means + SEM; 
whereby asterisks represent a significant difference from the drug-free control group. A paired 
t-test was used to calculate the areas in the diagram * P<0.05, **P< 0.01. A total of 13 
animals were used. The black column represents the control group. The white column depicts 
the drug-treated animals. The striped column indicates the results obtained with no animal 
connected to the chemiluminescent system. Note that chemical inhibition of the 
chemiluminescent signal through 10-3 M and 10-2 M amphetamine is not due to a 
physiological inhibition of AChE-release, but rather represents a direct chemical `quenching´. 
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Figure 21 shows the correlation between AChE-release and turns per minute. The left-hand 
point represents the 13 control animals. They produced 108% AChE and 0.06 turns per 
minute. The animals which were infused with 10-7 M amphetamine produced 132% AChE 
and 0.22 turns per minute. Those which received 10-6 M amphetamine generated 143% AChE 
and rotated 0.28 times per minute. Animals which were given 10-5 M amphetamine generated 
139% AChE and 0.22 turns per minute, while those which were infused with 10-4 M 
amphetamine produced 139% AChE and turned 0.25 times per minute. 
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3.1.4 The effect of systemic administration of amphetamine 
 
3.1.4.1 The systemic administration of amphetamine and its behavioural effect 
 
Amphetamine (1mg/kg in saline) was injected i.p. and the rats then tested immediately for 
enhanced motor-activity using the computer system to monitor the total distance moved in 
millimetres. The same procedure was carried out with control animals who were injected with 
a saline vehicle only. The computer system detected the movement with help of the LED in 
the animals headset (figure 22) and showed at which point (x and y) the animal travelled in 
terms of distance (mm) and time (in seconds). The sum of the distance travelled gave the total 
distance moved in a time period of 120 seconds. Paired t-tests showed a significant difference 
between control groups and amphetamine stimulation (P<0.001). The mean total distance 
moved was as follows: Treatment with saline only 2787 mm + 322 SEM, treatment with 
amphetamine 7493 mm + 406 SEM and after stimulation 4617 mm + 785 SEM, see figure 23. 
In contrast, systemic stimulation of the animal with 1mg amphetamine/kg i.p. produced a 
different pattern of behaviour from that seen with local administration. Typically, 
approximately 5 minutes after amphetamine injection, the animals became more active, 
moving around the entire box. The activity lasted for about one hour with the animal moving  
either in a contraversive or ipsiversive direction. A bias varying from animal to animal was 
observed, see figure 24. This increased activity was associated with an increase in release of 
AChE. 
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Figure 22: Animal movement monitored with an Antrak video-based animal tracking system 
with help of the LED in the animal’s headset. 
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Figure 23: Total distance moved (mm) during systemic stimulation with amphetamine 
(1mg/kg) compared to control groups injected with saline only, and approximately one hour 
following amphetamine stimulation. Results are expressed as means + SEM, asterisks 
represent a significant difference from drug-free control group, * P<0.05, *** P<0.001, paired 
t-test, n=10. 
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Figure 24: Cumulative data showing motor activity following i.p. treatment with saline (A); 
with amphetamine (B)-(E), and approximately one hour after amphetamine treatment (F). The 
diagram shows behaviour evoked by amphetamine stimulation during the first 480 seconds 
and approximately one hour later. The animal movement induced by systemic stimulation 
with amphetamine is monitored with an Antrak video-based animal tracking system. Different 
computer plotted pictures are shown, each covering in a period of 120 seconds. Total distance 
moved (in mm): (A) 788, (B) 3572, (C) 5268, (D) 6484, (E) 3421, (F) 2129. 
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3.1.4.2 The systemic administration of amphetamine and its effect on the release of AChE 
 
AChE-release was continuously monitored in relation to specific movements evoked by 
amphetamine stimulation (figure 26). The spontaneous release of AChE of 0.11 + 0.03 mU 
(n=9) was detected in perfusate of the substantia nigra. An application of amphetamine 
(1mg/kg) caused an increase in the spontaneous release of AChE which exceeded control 
conditions by approximately 40% (P<0.01, paired t-test; see figure 27). There was no increase 
seen following the injection of saline only (figure 25). Increased motor activity was associated 
with an increase in release of AChE. The raised concentration of AChE-release lasted for 
approximately one hour at a steady level. The diminution in movements was associated with a 
decrease in AChE-release. 
Even when amphetamine was administered systematically we were able to see a correlation 
between the level of AChE-release in the substantia nigra and behaviour measured in total 
distance moved - see figure 28. A increase in the level of AChE released led to an increase in 
the distance moved and vice versa. 
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Figure 25: A typical trace showing the chemiluminescent signal produced by adding 
decreasing concentrations of exogenous AChE (Sigma) to the system prior to animal 
attachment. The left hand side of the graph represents the spontaneous hydrolysis of ACh in 
vitro (background signal). A large signal peak due to blood/air contamination was 
experienced when connecting the animal. On-line detection of release of AChE in vivo can be 
observed between 4500 – 5000 seconds. AChE-release was stimulated with sterile saline i.p.. 
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Figure 26: A typical trace showing the chemiluminescent signal produced by adding 
decreasing concentrations of exogenous AChE (Sigma) to the system prior to animal 
attachment. The left hand side of the graph represents the spontaneous hydrolysis of ACh in 
vitro (background signal). A large signal peak due to blood/air contamination was 
experienced when connecting the animal. On-line detection of release of AChE in vivo can be 
observed upon 5500 seconds. AChE-release was stimulated with amphetamine i.p.. 
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Figure 27: The spontaneous release of AChE from substantia nigra shown as a basal value. 
The other two columns represent the control animals and the animals treated with systemic 
amphetamine. Results are expressed as means + SEM, asterisks represent a significant 
difference from the drug-free control group, ** P<0.01, paired t-test, n=9. 
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Figure 28: The correlation between AChE-release and total distance moved (mm). The basal 
value of 105% AChE was produced together with movement covering 1085 mm. The control 
animals produced 101% AChE and covered a distance of 2787 mm. Animals which were 
infused with amphetamine i.p. emitted 145% AChE and covered a distance of 7492 mm; r² 
=0.8878.  
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RESULTS 
3.2 THE RELEASE OF ACETYLCHOLINESTERASE IN THE 
PATHOLOGICAL BASAL GANGLION FOLLOWING 
AMPHETAMINE STIMULATION 
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3.2 The release of acetylcholinesterase in the pathological basal ganglion following 
amphetamine stimulation 
 
The objectives of the present study were to show the physiological and behavioural effects of 
intracerebral application of the neurotoxin 6-OHDA on the in vivo release of AChE in the 
substantia nigra of the rat. 
Parkinson’s disease arises from a selective and progressive degeneration of neuromelanin 
containing dopaminergic neurons which project from the substantia nigra to the striatum. 
In the present study, the neurotoxin 6-OHDA was used to disrupt/destroy the nigrostriatal 
pathway. This toxin was applied to one side of the brain. We expected to observe a marked 
gradient of nigrostriatal damage, including unilateral nigral and striatal dopamine depletion 
between the two sides of the animal’s brain, and that stimulation of the neurotoxin-treated 
side would yield observable changes in movement. 
6-OHDA toxicity is due to autoxidation. It is taken up by dopaminergic and noradrenergic 
neurones. It is well documented that this neurotoxin can induce a Parkinson-like motor-deficit 
in animal models (Kaakkola and Teräväinen1990). 
The spontaneous and evoked release of AChE in vivo was detected and quantified using the 
on-line chemiluminescent system. 
 
 
3.2.1 The histological verification of cannulae placements 
 
Upon completion of each experiment, each animal was heavily anaesthetised, decapitated, and 
the brain removed and dissected. Verification of the placement of the nigral cannulae was 
achieved by an histological examination of 42 µm frozen cut sections stained with cresyl 
violet (figure 29). 
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Figure 29: A section of the rat brain stained with cresyl violet (width: 42 µm), showing the tip 
of a push-pull cannula placement in the substantia nigra, as marked by an asterisk. Stereotaxic 
co-ordinates are given in the text. 
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3.2.2 The effect of a local administration of amphetamine 
 
3.2.2.1 The local administration of amphetamine: Behavioural observations 
 
The animals moved spontaneously once they had recovered from anaesthesia. Animals pre-
treated with 6-OHDA or those which had been sham-operated did not appear to be any 
different to naive animals. No obvious changes in posture, general health/condition or 
movement were noted following surgery. However, abnormal changes in movement or 
rotational behaviour were noted 3 weeks after neurotoxin treatment. Some animals became 
aggressive and gnashed their teeth, and all displayed high circling movement. Sham-operated 
animals and those treated with neurotoxin were locally stimulated with amphetamine 10-7 M 
to 10-2 M. Each concentration of amphetamine was infused over a period of five minutes in 
ACSF. In order to directly compare the effects of the different concentration of amphetamine 
in the substantia nigra, each concentration was infused under the same conditions. Figure 30 
shows the circling behaviour prior to amphetamine infusion and that observed during the 
infusion of different concentrations of amphetamine. A paired t-test revealed a significant 
difference between high basal circling, 0.89 + 0.14 SEM turns/min and 10-7 M, 0.66 + 0.08 
SEM turns /min, (P<0.05); 10-6 M, 0.52 + 0.09 SEM turns/min, (P<0.01); 10-5 M, 0.39 + 0.09 
SEM turns /min, (P< 0.001); 10-4 M, 0.21 + 0.05 SEM turns/min, (P<0.001); 10-3 M, 0.17 + 
0.04 SEM turns/min, (P<0.001). The number of turns per minute decreased when the 
concentrations of amphetamine were increased, until a normal rotating behaviour was 
achieved similar to that of naive animals. Both ipsiversive turning (towards side of infusion) 
and contraversive turning (away from side of infusion) was observed following local 
amphetamine treatment (figure 31). 
Different behaviour was seen following infusion of 10-2 M amphetamine. The resulting rate of 
turns per minute observed with this concentration was brought about by other biochemical 
reactions produced by the extremely high level of amphetamine. A large variation was 
observed in the intensity of circling of between 0.15 and 5.8 turns/min, mean + SEM, 1.41 + 
0.65 turns/min (P<0.42). 
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Figure 30: The number of turns per minute exhibited during the 15 minutes following each of 
the 6 consecutive amphetamine concentrations infused into the substantia nigra via the push-
pull cannula, and prior to infusion with ACSF only. Results are expressed as means + SEM; 
asterisks represent a significant difference compared to levels prior to amphetamine; * P<0.05, 
** P<0.01, *** P<0.001; paired t-test. The number of animals used for each concentration 
was 10. 
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Figure 31: Animals pre-treated with 6-OHDA. (A) Animal movement prior to infusion with 
amphetamine, monitored with an Antrak video-based animal tracking system. Computer 
plotted picture, total distance moved: 8509 mm, time elapsed: 120 seconds. (B) Animal 
movement induced by local stimulation with amphetamine (in the substantia nigra via the 
push-pull cannula), monitored with an Antrak video-based animal tracking system. Computer 
plotted picture, total distance moved: 3791 mm, time elapsed: 120 seconds, amphetamine 
dosage:  10-3 M. 
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There was a different type of circling seen in sham-operated animals compared with animals 
pre-treated with 6-OHDA. Sham-operated animals showed a similar behaviour pattern to 
naive animals, see figures 32 and 33. The number of turns per minute was as follows: prior to 
infusion 0.24 turns/min + 0.06 SEM; 10-7 M 0.32 turns/min + 0.06 SEM (P<0.36); 10-6 M 0.5 
turns/min +0.06 SEM (P<0.05); 10-5 M 0.5 turns/min + 0.13 SEM (P<0.22); 10-4 M 0.43 
turns/min + 0.06 SEM (P<0.06); 10-3 M 0.33 turns/min + 0.04 SEM (P<0.27); 10-2 M 2.39 
turns/min + 0.73 SEM (P<0.10). 6-OHDA pre-treated rats were more active, restless and 
aggressive, scoring more turns per minute before amphetamine stimulation. During 
stimulation with different concentrations of amphetamine (10-7 M to 10-2 M) the animals pre-
treated with 6-OHDA became calmer, eventually reaching a normal pattern of behaviour. 
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Figure 32: The number of turns per minute exhibited during the 15 minutes following each of 
the 6 consecutive amphetamine concentrations infused into the substantia nigra via the push-
pull cannula, and prior to infusion with ACSF only. Results are expressed as means + SEM; 
asterisks represent a significant difference compared to levels prior to amphetamine infusion; 
* P<0.05; paired t-test. The number of animals used for each concentration was 10. 
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Figure 33: Sham-operated animals. (A) Animal movement prior to infusion with 
amphetamine monitored with an Antrak video-based animal tracking system. Computer 
plotted picture, total distance moved: 2896 mm, time elapsed: 120 seconds. (B) Animal 
movement induced by local stimulation with amphetamine (in the substantia nigra via a push-
pull cannula), monitored with an Antrak video-based animal tracking system. Computer 
plotted picture, total distance moved: 6180 mm, time elapsed: 120 seconds, amphetamine 
dosage: 10-2 M. 
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3.2.2.2 The local administration of amphetamine and its effect on AChE-release 
 
Figure 34 shows the spontaneous release of AChE in the substantia nigra of 3-week, 6-
OHDA-treated animals compared to naive and sham-operated animals. The spontaneous 
release of AChE in the substantia nigra was significantly reduced by 68% following pre-
treatment with 6-OHDA, 3-week lesion, P<0.01, t-test. The basal AChE perfusate value of 
0.04 + 0.01 mU (n=22) was detected. 
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Figure 34 shows the spontaneous release of AChE in the substantia nigra of naive animals, 3-
week 6-OHDA-treated animals, and sham-operated animals. Results are expressed as means + 
SEM; n=10 for each group. Asterisks represent a significant difference from corresponding 
neurotoxin free control group; **P< 0.01, t-test. 
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The effect of local application of amphetamine on the spontaneous release of AChE into the 
substantia nigra on 3-week, 6-OHDA treated animals is shown in figure 35. 
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Figure 35: A typical trace showing the chemiluminescent signal produced by adding 
decreasing concentrations of exogenous AChE (Sigma) to the system prior to animal 
attachment. The left hand side of the graph represents the spontaneous hydrolysis of ACh in 
vitro (background signal). A large signal peak due to blood/air contamination was 
experienced when connecting the animal. On-line detection of release of AChE in vivo; 
AChE-release was stimulated intranigrally with 10-7 M to 10-4 M. 
 
 
 
Figure 36 shows the effect of application of amphetamine 10-7 M to 10-4 M administered 
locally to the substantia nigra on the spontaneous release of AChE on 6-OHDA pre-treated 
animals. Release of nigral AChE, evoked in this way, increased 30.8%, P<0.18, 10-7 M; 
70.6%, P<0.28, 10-6 M; 67.6%, P<0.08, 10-5 M; 13%, P<0.74, 10-4 M over basal conditions. 
There was no significant difference in the release of AChE between any of the experimental 
conditions. However, 10-4 M amphetamine treatment had no effect on the increase in the 
percentage release of AChE, when the evoked data was expressed as a percentage of basal 
levels. In addition, for each concentration of amphetamine was a large variation in AChE 
released. 
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Figure 36: The spontaneous release of AChE in the substantia nigra of 3-week post-operative 
rats prepared with 6-OHDA. The spontaneous release is expressed as a percentage. Both the 
basal value and that achieved with amphetamine-stimulated animals are shown. Results are 
expressed as means + SEM; paired t-test, n=10. The black column represents the 6-OHDA 
animals which were not treated with amphetamine. The white column represents the drug-
treated 6-OHDA animals. 
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The effect of local application of amphetamine on the spontaneous release of AChE in the 
substantia nigra at sham-operated animals shows similar results to those achieved with naive 
animals (figure 37). 
Mean + SEM basal AChE perfusate value was 0.21 + 0.04 mU (n=10). Amphetamine at 10-7 
M caused significant enhancement of 27.5%, P<0.05, in the release of AChE; 10-6 M 51.5%, 
P<0.05; 10-5 M 55%, P<0.05 and 10-4 M 51.5%, P<0.05 (figure 38). The increase in the level 
of AChE released by sham-operated animals (also with 10-5 M to 10-4 M) reached a plateau, in 
the same way it did in naive animals. 
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Figure 37:  A typical trace showing the chemiluminescent signal produced by adding 
decreasing concentrations of exogenous AChE (Sigma) to the system prior to animal 
attachment. The left hand side of the graph represents the spontaneous hydrolysis of ACh in 
vitro (background signal). A large signal peak due to blood/air contamination was 
experienced when connecting the animal. On-line detection of release of AChE in vivo; 
AChE-release was stimulated intranigrally with 10-7 M to 10-4 M. 
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Figure 38: The spontaneous release of AChE in the substantia nigra of sham-operated animals 
(expressed as a percentage). The diagram shows basal values and those achieved following 
amphetamine stimulation. Results are expressed as means + SEM; asterisks represent a 
significant difference from basal value; *P<0.05, paired t-test, n=10. The black column 
represents non-amphetamine-treated sham-operated animals, with the white column 
representing drug-treated sham-operated animals. 
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A correlation between the level of AChE released in the substantia nigra and the number of 
turns per minute was only seen by the sham-operated rats, see figure 39. A correlation existed 
between the level of AChE released in the substantia nigra and behaviour and vice versa. An 
increased number of turns per minute corresponded to an increase in the level of AChE 
released in the CSF, a higher concentration of AChE in the CSF correspond to more turns/min. 
However, higher concentration of amphetamine has an influence on AChE-release in the 
substantia nigra, but can influence the number of turns per minute. 
There was no correlation seen between AChE-release and the number of turns per minute in 
neurotoxin treated animals, see figure 40. 
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Figure 39: The correlation between AChE-release and the number of turns per minute. The 
basal values were 104.5% AChE with 0.24 turns per minute. Following infusion of 10-7 M 
amphetamine, 132% AChE was released with 0.32 turns per minute. With 10-6 M 
amphetamine, the level of AChE-release rose to 156% with 0.5 turns per minute. An infusion 
of 10-5 M amphetamine produced 159.5% AChE and 0.5 turns per minute, and, last but not 
least, 10-4 M amphetamine produced 156% AChE and 0.43 turns per minute; r2=0.9194. 
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Figure 40: The correlation between AChE-release and the number of turns per minute. The 
basal values were 73.2% AChE with 0.89 turns per minute. Following infusion of 10-7 M 
amphetamine, 104% AChE was released with 0.66 turns per minute. With 10-6 M 
amphetamine, the level of AChE-release rose to 143.8% with 0.52 turns per minute. An 
infusion of 10-5 M amphetamine produced 140.8% AChE and 0.39 turns per minute, and, last 
but not least, 10-4 M amphetamine produced 86.2% AChE and 0.21 turns per minute. 
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3.2.3 The effect of systemic administration of amphetamine 
 
3.2.3.1 Systemic administration of amphetamine: Behavioural observations 
 
Any spontaneous or induced animal movements that occurred during the perfusion period 
were monitored using an Antrak video-based animal tracking system, which was used in 
conjunction with the on-line chemiluminescent system. This system involves a computerised 
tracking of a LED , in and around a pre-set area within the study-arena. The computer plotted 
the animal’s movements within a pre-set time period. The animal’s movements were also 
expressed as a number of 360o turns. 
Amphetamine (1mg/kg in saline) was injected intraperitoneally and the animals treated with 
6-OHDA were tested immediately for changes in motor-activity. A paired t-test showed a 
significant difference of prior amphetamine stimulation and during the stimulation period 
(P<0.01). The mean number of turns per minute was as follows: Prior to amphetamine 
stimulation, I observed 0.66 turns per minute + 0.04 SEM. Following treatment with 
amphetamine, the rate increased to 2.65 turns per minute + 0.53 SEM, see figure 41. 
Compared to naive animals, lesioned animals showed a high basal motor-activity, constantly 
changing between an ipsiversive and contraversive direction (figure 42). 
Amphetamine caused ipsiversive as well contraversive rotation in the rats with unilateral 6-
OHDA-induced lesions of the nigro-striatal dopamine pathway. The mean total distance 
moved reached 21278 mm + 964 SEM (figure 43). 
In comparison, sham-operated animals showed similar behaviour to naive animals (figures 44 
and 45). Typically, the animals became more active approximately 5 minutes after 
amphetamine injection, rotating contraversively or ipsiversively. A paired t-test showed a 
significant difference between basal activity and amphetamine stimulation (P<0.001). The 
mean total distance moved prior to stimulation was 2885 mm + 107 SEM, increasing to 6643 
mm + 191 SEM following treatment with amphetamine i.p.. 
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Figure 41: The number of turns per minute during systemic stimulation with amphetamine 
(1mg/kg) on operated animals, compared to prior i.p. stimulation. Results are expressed as 
means + SEM, asterisks represent a significant difference from drug-free control group, 
**P<0.01, paired t-test, n=10. 
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Figure 42: The number of turns per minute displayed by animals with a unilateral 6-OHDA-
induced lesion of the nigro-striatal dopamine pathway, as compared to naive animals. Results 
are expressed as means + SEM, asterisks represent a significant difference from naive animals, 
***P<0,001, paired t-test, n=10. 
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Figure 43: 6-OHDA pretreated animals. Cumulative data showing motor-activity prior to 
amphetamine stimulation (a)-(b) and after i.p. treatment with amphetamine (c)-(f). The 
behaviour during the first 480 seconds evoked by amphetamine stimulation is shown. The 
animal movement was monitored with an Antrak video-based animal tracking system. The 
different computer-plotted pictures show periods of 120 seconds each. Total distance moved 
(in mm): (a) 8509, (b) 8134, (c) 21408, (d) 19470, (e) 20319, (f) 23913. 
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Figure 44: The total distance moved (in mm) during systemic stimulation with amphetamine 
(1mg/kg) of sham-operated animals, compared to their condition prior to i.p. stimulation. 
Results are expressed as means + SEM, asterisks represent a significant difference from drug-
free control group, ***P<0,001, paired t-test, n=10. 
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Figure 45: Sham-operated animals. Cumulative data showing motor-activity (a) prior to 
amphetamine stimulation and (b)-(f) after i.p. treatment with amphetamine. The behaviour 
during the first 600 seconds evoked by amphetamine stimulation is shown. The animal 
movement was monitored with an Antrak video-based animal tracking system. The different 
computer plotted pictures present periods of 120 seconds each. Total distance moved (in mm): 
(a) 1993, (b) 6454, (c) 5879,(d) 6243, (e) 6612, (f) 6186. 
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3.2.3.2 The systemic administration of amphetamine and its effect on the release of AChE 
 
When the push-pull cannula was correctly implanted in the substantia nigra of the operated rat, 
the light signal produced is shown in figure 46. 
Initially, a large signal was produced, attributable to either blood (in the early part of the 
perfusate) or air (when connecting the outflow tubing to the side arm of the cannula). This 
raised level of release gradually fell to a level that was lower than that of naive or sham-
operated animals (figure 42). This signal represented a spontaneous release of AChE from the 
rat substantia nigra of 0,04 + 0,008 mU (n=10). 
A paired t-test showed that the application of amphetamine (1mg/kg) caused a significant rise 
in the spontaneous release of AChE of approximately 238% over basal conditions (P<0,001., 
see figure 47). 
 
With the systemic administration of amphetamine, there was increase in the level of motor 
activity directly associated with an increase in the release of AChE. There was a correlation 
seen between AChE-release in the substantia nigra and behaviour measured in total distance 
moved, see figure 48. 
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Figure 46: A typical trace showing the chemiluminescent signal produced by adding 
decreasing concentrations of exogenous AChE (Sigma) to the system prior to animal 
attachment. The left hand side of the graph represents the spontaneous hydrolysis of ACh in 
vitro (background signal). A large signal peak due to blood/air contamination was 
experienced when connecting the animal. On-line detection of release of AChE in vivo; 
AChE-release was stimulated with amphetamine i.p.. 
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Figure 47: The spontaneous release of AChE from the substantia nigra of operated animals, 
shown as basal and treated with the systemic application of amphetamine. Results are 
expressed as means + SEM, asterisks represent significant difference from the drug-free 
control group, ***P<0,001, paired t-test, n=10. 
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Figure 48: The correlation between AChE-release and the number of turns per minute. The  
basal values were 77.5% AChE with 0.66 turns per minute. Following application of 
amphetamine i.p. the values increased to 315.8% AChE with 2.65 turns per minute; r2=1. 
Results 113
The effect of a systemic application of amphetamine on the spontaneous release of AChE in 
the substantia nigra of sham-operated animals showed 0,21 + 0,04 mU (n=10) in the perfusate. 
Figure 49 shows the effect of application of amphetamine. The release of nigral-AChE 
evoked in this way increased 52% in comparison to basal levels (paired t-test, P<0,01, n=10), 
see figure 50. 
A correlation between AChE release in the substantia nigra and behaviour was even observed 
in sham-operated animals, see figure 51. 
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Figure 49: A typical trace showing the chemiluminescent signal produced by adding 
decreasing concentrations of exogenous AChE (Sigma) to the system prior to animal 
attachment. The left hand side of the graph represents the spontaneous hydrolysis of ACh in 
vitro (background signal). A large signal peak due to blood/air contamination was 
experienced when connecting the animal. On-line detection of release of AChE in vivo; 
AChE-release was stimulated with amphetamine i.p.. 
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Figure 50: The spontaneous release of AChE from substantia nigra of sham-operated animals 
shown both as basal and in animals treated with systemic application of amphetamine. Results 
are expressed as means + SEM, asterisks represent significant difference from the drug-free 
control group, **P<0,01, paired t-test, n=10. 
Results 115
 
SHAM-OPERATED ANIMALS
CORRELATION
0
20
40
60
80
100
120
140
160
180
0 2000 4000 6000 8000
total distance moved (mm)
pe
rc
en
ta
ge
 s
po
nt
an
eo
us
 re
le
as
e
o
f A
Ch
E
 
Figure 51: The correlation between AChE-release and the total distance moved (mm). The 
basal values observed were 102% AChE with total movement of 2885 mm. Following the 
application of amphetamine i.p., the level of AChE-release increased to 154% and the 
distance travelled to 6643 mm. 
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3.2.3.3 The dopamine content of tissue samples 
 
Punches of tissue were removed from both striata. DOPAC (data not present) and dopamine 
were quantified by high performance liquid chromatography (HPLC: C18 reverse phase 
column). 
Figure 52 shows the effect of the neurotoxic pre-treatment on the dopamine content of the 
striata versus the untreated side of the brain. The dopamine content of the treated striata is 
expressed relative to the respective non-treated striata (taken as approximately 100% + SEM). 
Dopamine levels were significantly reduced by 76% following pre-treatment with 6-OHDA. 
A paired t-test revealed that in operated animals there was a significant decrease in dopamine 
content of the striata receiving the injection, compared to the untreated striata (P<0,01), see 
figure 52. 
In addition, a paired t-test carried out on striatum samples taken from control animals (sham-
operated) showed that there was no significant difference in dopamine content between the 
treated (sterile saline) and non-treated side, see figure 52. 
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Figure 52: The dopamine content of striatal tissue samples from the non-treated side (left) and 
the treated side (right) of rats treated with 6-OHDA (3-week after operation), sterile saline and 
their respective drug-free controls groups. Results are expressed as mol/ml (means + SEM); 
n=10 for each group. Asterisks represent a significant difference from the treated side; 
**P<0,01, paired t-test. 
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3.2.3.4 The location of TH immunreactivity in the substantia nigra 
 
Dopaminergic neurons of the substantia nigra are well known to be pivotal in normal and 
pathological motor-control. 
Anatomical analysis of post-mortem tissue revealed that the injection of 6-OHDA into the 
medial forebrain bundle resulted in substantial reduction of TH-immunoreactive neurons in 
the substantia nigra pars compacta and substantia nigra pars reticulata. This relative sparing of 
dopaminergic cells in the substantia nigra pars compacta reflects the pattern of cell loss in 
brains of patients with Parkinson’s disease (German et al. 1989, Goto et al. 1989). Typically, 
animals showed 10% or fewer TH-immunreactive neurons in the treated SNpc than in the 
intact side of the brain (figure 53). 
There was no obvious or marked difference in TH-staining when samples from both the 
treated and untreated brain-hemispheres of sham-operated animals were compared (figure 54). 
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Figure 53: TH+ neurons in a parasaggital section of the mesencephalon of the lesioned rat. 
Photograph (A) shows the lack of cell bodies in the substantia nigra following a partial 3-
week treatment with 6-OHDA. Photograph (B) shows TH staining observed in a brain slice, 
from untreated side under magnification. (Magnification x 100, bar indicates 100 µm). 
Results 120
 
 
 
 
 
(B) 
 
Figure 54: The anatomical features of (A) treated (sterile saline) substantia nigra and (B) 
untreated substantia nigra in sham-operated animals. The pictures show the 
immunhistochemical staining of TH+ cells; (magnification x 100, bar indicates 100 µm). 
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3.2.3.5 The location of AChE immunreactivity in the substantia nigra 
 
Various studies suggest a relationship between AChE and dopamine in the substantia nigra. 
Figure 55 shows the rat substantia nigra pars compacta stained for AChE in 6-OHDA pre-
treated animals, following immunhistochemical staining with 3D10. These rat sections clearly 
show cell bodies staining for AChE. 
We could see that an injection of 6-OHDA into the medial forebrain bundle resulted in a 
reduction of AChE-immunreactive neurons in the SNpars compacta. But there was no obvious 
or marked difference in AChE staining when samples from both treated (sterile saline) and 
untreated side of sham-operated animals were compared (data not shown). 
 
Results 122
 
 
 
 
 
(B) 
 
Figure 55: Photograph of AChE immunhistochemical staining of a treated animal. (A) clearly 
shows the lack of cell bodies in the substantia nigra following a partial 3-week treatment with 
6-OHDA. (B) shows AChE staining in a slice of the untreated side of the brain under 
magnification. (Magnification x 100, scale bar = 100 µm). 
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RESULTS 
3.3 THE RELEASE OF ACETYLCHOLINESTERASE 
IN RELATION TO OTHER DRUG STIMULATIONS 
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3.3 The release of acetylcholinesterase in relation to other drug stimulations 
 
The objective of this study was to use drugs other than amphetamine to determine whether 
they had an influence on the intranigral AChE and on behaviour. The following compounds 
were used: apomorphine, quinpirole, NMDA. 
In addition, an histological examination of all groups analysed indicated that cannulae 
placements were distributed evenly throughout the substantia nigra. 
 
 
3.3.1 Apomorphine applied to the on-line system without an animal connected 
 
It was found that apomorphine had a similar quenching effect to amphetamine (10-3 M to 10-2 
M), 5-HT (10-6 M) and α-methyl 5-HT (10-6 M) on this system, when added locally (figure 
56). Therefore, it was not possible to stimulate the animal locally using apomorphine. 
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Figure 56: A typical trace showing the chemiluminescent signal produced by adding 
decreasing concentrations of exogenous AChE (Sigma) in mU/ml to the system prior to 
apomorphine testing (10-4 M). When apomorphine was added to the system, a loss of the 
chemiluminescent signal was observed. 
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3.3.2 The effect of the systemic administration of apomorphine 
 
An additional set of experiments was carried out on naive animals and toxicated animals 
using apomorphine (1mg/kg in 0.2 mg/kg ascorbic acid). It was not possible to measure the 
nigral release of AChE in naive animals due to technical difficulties. 
 
3.3.2.1 The systemic administration of apomorphine to naive animals 
 
Apomorphine was injected intraperitoneally and the naive animals tested immediately for 
enhanced motor activity. A paired t-test showed a significant difference between the level of 
activity before and after i.p. stimulation with apomorphine (P<0.05). The mean total distance 
moved prior to treatment was 2490 mm + 100 SEM. This increased to 3687 mm + 114 SEM 
following treatment with apomorphine (figure 57). 
 
The systemic administration of apomorphine resulted in a characteristic behaviour pattern. 
The animals often preferred to spread themselves out on the bedding, moving the head slowly, 
rotating firstly in a contraversive then in an ipsiversive direction, ending with permanent 
ipsiversive rotating behaviour which lasted for about 20 minutes (figure 58). 
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Figure 57: The total distance moved (mm) during systemic stimulation with apomorphine 
(1mg/kg), compared to the level of movement observed prior to stimulation. Results are 
expressed as means + SEM, with asterisks representing a significant difference between the 
test animals and the drug-free control group, *P<0.05, paired t-test, n=3. 
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Figure 58: Cumulative data showing motor-activity prior to stimulation (a) and after i.p. 
treatment with apomorphine (b)-(f). The behaviour observed during the first 600 seconds 
following apomorphine stimulation is shown. The animal movement induced by systemic 
stimulation with apomorphine was monitored with an Antrak video-based animal tracking 
system. The different computer plotted pictures show periods of 120 seconds each. Total 
distance moved (in mm): (a) 1559, (b) 3177, (c) 3725, (d) 3081, (e) 3650, (f) 3542. 
 
 
 
3.3.2.2 The systemic administration of apomorphine to 6-OHDA treated animals 
 
Apomorphine was injected intraperitoneally and the treated rats were immediately observed 
for changes in motor activity using the computer system to monitor total distance moved. 
Furthermore, the number of 360o degree turns completed by the animals were counted. 
In comparison to naive animals, the treated animals showed a prominent basal circling in a 
contraversive as well as ipsiversive direction. Soon after apomorphine stimulation i.p., the 
circling behaviour ceased almost completely - see figure 59. 
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Figure 59: Cumulative data showing motor activity prior to stimulation (a)-(c) and after i.p. 
treatment with apomorphine (d)-(f). Animal movement was monitored with an Antrak video-
based animal tracking system. The different computer-plotted pictures show periods of 120 
seconds each. Total distance moved (mm): (a) 6824, (b)8965, (c) 6569, (d) 3248, (e) 1706, (f) 
3182. 
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A paired t-test showed a significant difference between the basal circling and the circling 
caused by apomorphine (P<0.05). The mean number of turns per minute was as follows: The 
basal rate of circling was 0.40 turns per minute + 0.04 SEM. This decreased to 0.07 turns per 
minute + 0.07 SEM following treatment with apomorphine (figure 60). 
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Figure 60: The number of turns per minute during systemic stimulation with apomorphine 
(1mg/kg) compared to the basal behaviour of toxicated animals. Results are expressed as 
means + SEM, with asterisks representing a significant difference between the test animals 
and the drug-free group, *P<0.05, paired t-test, n=3. 
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AChE-release was permanently monitored (figure 61) to observe specific movements brought 
about by apomorphine stimulation. A paired t-test showed that neurotoxic pre-treatment 
significantly reduced the spontaneous release of AChE from the rat substantia nigra (P<0,01, 
n=22), see 3.2.2.2 fig. 34. 
Pre-treatment with 6-OHDA led to a significant reduction of approximately 68% in the 
spontaneous release of AChE in free moving animals (P<0.01, t-test). 
In contrast, application of apomorphine i.p. effected a rise in the spontaneous release of AChE 
of approximately 43% above basal conditions (P<0.01, paired t-test, see figure 62). 
An increase of nigral AChE was seen in conjunction with a decrease of motor activity. The 
application of apomorphine resulted in a return to normal behaviour. The level of intranigral 
AChE increased to a level exceeding that normally observed (figure 63). 
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Figure 61: A typical trace showing the chemiluminescent signal produced by adding 
decreasing concentrations of exogenous AChE (Sigma) to the system prior to animal 
attachment. The left hand side of the graph represents the spontaneous hydrolysis of ACh in 
vitro (background signal). A large signal peak due to blood/air contamination was 
experienced when connecting the toxicated animal. This is followed by the on-line detection 
of AchE-release in vivo; AChE-release was stimulated with apomorphine i.p.. 
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Figure 62:  The spontaneous release of AChE in the substantia nigra after 3-weeks treatment 
in animals. The graph shows the basal values and those achieved following the systemic 
injection of apomorphine. Results are expressed as means + SEM, with asterisks representing 
a significant difference between the test animals and the drug-free control group, **P<0.01, 
paired t-test, n=3. 
 
Results 134
Correlation between AChE release 
and turns/min
6-OHDA animals
systemic administration of apomorphine
0
20
40
60
80
100
120
140
0 0,1 0,2 0,3 0,4 0,5
turns/minute
pe
rc
en
ta
ge
 
sp
on
ta
n
eo
u
se
 
re
le
as
e 
of
 
A
Ch
E
 
 
Figure 63: The correlation between AChE-release (%) and turns per minute. The basal values 
correspond to 81% AChE and 0.40 turns per minute. Following application of apomorphine 
i.p., values of 124% AChE and 0.07 turns per minute were observed. 
 
 
For the dopamine content of tissue samples, see 3.2.3.3. For the location of TH 
immunreactivity, see 3.2.3.4. 
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3.3.3 The effect of quinpirole administration on naive animals 
 
It was not possible to measure the nigral release of AChE in the substantia nigra due to 
technical difficulties. 
Quinpirole (10-2 M in ACSF) was intranigrally infused into naive animals over a five-minute 
period. The circling behaviour was measured at the point when quinpirole arrived in the 
substantia nigra for 15 minutes. 
Prior to infusion, the basal level of ipsiversive circling exhibited by the animals (n=3) was 
very modest. A paired t-test revealed no significant difference (P=0.422) between 
spontaneously circling behaviour, 0.13 + 0.07 SEM turns/min and 10-2 M, 0.2 + 0 SEM 
turns/min (figure 64). 
 
No noticeable changes in animal behaviour or movement were observed following lower 
concentrations of quinpirole. Local infusion of 10-2 M quinpirole into one substantia nigra 
lead to a characteristic behaviour pattern (figure 65). The animals started contraversive low 
intensity circling, exhibiting a slight shaking of the head. They either fell onto their backs or 
came to rest on their side. 
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Figure 64 shows the number of turns per minute exhibited following infusion with ACSF, and 
during the 15 minutes following the infusion of 10-2 M quipirole into the substantia nigra via 
the push-pull cannula. Results are expressed as means + SEM; no significant difference was 
seen between spontaneous circling behaviour and stimulated circling behaviour. P=0.422, 
paired t-test, n=3. 
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Figure 65 (A): Animal movement prior to infusion with quinpirole, monitored with an Antrak 
video-based animal tracking system. Computer plotted picture, total distance moved: 1639 
mm, time elapsed: 120 seconds. Figure 65 (B): Animal movement induced by local 
stimulation with quinpirole, monitored with an Antrak video-based animal tracking system. 
Computer plotted picture, total distance moved: 2855 mm, time elapsed: 120 seconds, 
quinpirole dosage: 10-2 M. 
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3.3.4 The effect of NMDA administration on naive animals 
 
Before the experiments were performed, the possibility that the introduction of NMDA into 
the chemiluminescent assay could change the light-emitted signal was investigated. 
The light emitted signal was the same when 10-4 M or 10-2 M NMDA was subjected to the 
chemiluminescent reaction. Therefore, it was possible to study the effect of perfusion into the 
substantia nigra of NMDA on release of AChE without this substance having a direct effect 
on the light-emitted signal. 
A stock solution of NMDA (10-2 M) was prepared in ACSF then diluted with ACSF (10-4 M). 
NMDA was introduced for five-minute periods to the substantia nigra via the push-pull 
cannula and a recovery period at least 15 minutes was allowed between consecutive 
applications. Both the behaviour of the animals and the release of AChE were monitored 
during NMDA treatment. Circling behaviour was measured in turns per minute. 
There was a expressive change in the behaviour of the three animals when 10-2 M NMDA was 
perfused through the substantia nigra. Lower concentrations of NMDA showed no apparent 
effect. A paired t-test revealed a significant difference in the animals before and after infusion 
0.22 + 0.02 SEM turns/min and 10-2 M 5.62 + 1.06 SEM turns/min (P<0.05), see figure 66. 
There was no significant difference at 10-4 M, 0.65 + 0.193 SEM turns/min (P=0.13). Before 
infusion, the animals exhibited modest basal ipsiversive or contraversive circling, with the 
preference varying from animal to animal. Local infusion of one substantia nigra with NMDA 
resulted in excessive circling behaviour (figure 67). The first indications that NMDA had 
reached the substantia nigra were as follows: The animals sat up on their hind legs, fell onto 
one side and began to burrow through the bedding. Following this, they began circling rapidly. 
In most cases, the animals exhibited ipsiversive circling behaviour at high speed until the 
point of exhaustion. 
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Figure 66: The number of turns per minute exhibited during the 15 minutes following each of 
the 2 consecutive NMDA concentrations infused into the substantia nigra via the push-pull 
cannula, and prior to infusion with ACSF only. Results are expressed as means + SEM; with 
asterisks representing a significant difference compared to levels prior to NMDA infusion, 
*P<0.05, paired t-test. The number of animals used for each concentration was 3. 
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Figure 67 (A): Animal movement prior to infusion with NMDA, monitored with an Antrak 
video-based animal tracking system. Computer plotted picture, total distance moved: 2818 
mm, time elapsed: 120 seconds. Figure 67 (B): Animal movement induced by local 
stimulation with NMDA, monitored with an Antrak video-based animal tracking system. 
Computer plotted picture, total distance moved: 9357 mm, time elapsed: 120 seconds, NMDA 
dosage: 10-2 M. 
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The baseline release of AChE was 0.16 + 0.03 SEM mU, n=3. When the release of AChE was 
expressed as the percentage release of AChE in comparison to baseline release (which was 
taken as 100%), there was no significant difference (paired t-test, P=0.31) in the release of 
AChE between any of the experimental conditions (10-4 M, 108%) apart from 10-2 M (121%, 
P<0.05), see figures 68 and 69. 
Following local administration of NMDA, a correlation was seen between AChE-release in 
the substantia nigra and the behaviour as measured in turns per minute, see figure 70. An 
increase in the number of turns per minute corresponds to an increased release of AChE. 
However, I was only able to observe an effect on the level of AChE-release when a very high 
dose of NMDA was administered. 
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Figure 68: A typical trace showing the chemiluminescent signal produced by adding 
decreasing concentrations of exogenous AChE (Sigma) to the system prior to animal 
attachment (between 0 – 4000 seconds). The left hand side of the graph represents the 
spontaneous hydrolysis of ACh in vitro (background signal at 4500 seconds). A large signal 
peak due to blood/air contamination was experienced when connecting the animal. This is 
followed by the on-line detection of AChE-release in vivo (up to 7000 seconds). intranigral 
stimulation of AChE-release with NMDA 10-4 and 10-2 M. 
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Figure 69: The spontaneous release of AChE in the substantia nigra of control and NMDA-
treated rats, expressed as a percentage. Results are shown as means + SEM; asterisks 
represent a significant difference between the test animals and the drug-free control group, 
*P<0.05, paired t-test, n=3. 
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Figure 70: The correlation between AChE-release and turns per minute. The values produced 
by the control animals were 94% AChE and 0.22 turns per minute. The animals which 
received 10-4 M NMDA produced 108% AChE and 0.65 turns per minute. Those infused with 
10-2 M NMDA emitted 123% AChE and produced 5.62 turns per minute; r2=0.83, n=3. 
